0001574774-20-000104.txt : 20201029 0001574774-20-000104.hdr.sgml : 20201029 20201029161411 ACCESSION NUMBER: 0001574774-20-000104 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20201029 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201029 DATE AS OF CHANGE: 20201029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTELEMETRY, INC. CENTRAL INDEX KEY: 0001574774 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 462568498 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55039 FILM NUMBER: 201272801 BUSINESS ADDRESS: STREET 1: 1000 CEDAR HOLLOW ROAD CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 610-729-7000 MAIL ADDRESS: STREET 1: 1000 CEDAR HOLLOW ROAD CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: BioTelemetry, Inc. DATE OF NAME CHANGE: 20130418 8-K 1 beat-20201029.htm 8-K beat-20201029
BioTelemetry, Inc.00015747748-KFALSE00015747742020-10-292020-10-29

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): October 29, 2020
beat-20201029_g1.jpg
BioTelemetry, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware000-5503946-2568498
(State or other jurisdiction(Commission(IRS Employer
of incorporation)File Number)Identification No.)
 
1000 Cedar Hollow Road
Malvern, Pennsylvania19355
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (610) 729-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareBEATNASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02 Results of Operations and Financial Condition.
On October 29, 2020, BioTelemetry, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2020. Such information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. A copy of the press release is included herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit NumberExhibit Title
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BioTelemetry, Inc.
Date: October 29, 2020
By:/s/ Heather C. Getz
Name:Heather C. Getz, CPA
Title:
Executive Vice President, Chief Financial and Administrative Officer


 EX-99.1 2 beat1029208kex991.htm EX-99.1 Document
    Exhibit 99.1
beatlogoa111.jpg

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results
Posts Record Quarterly Revenue Amidst Rapid Recovery

Malvern, PA – October 29, 2020 – BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended September 30, 2020.

Quarter Highlights

•Recognized quarterly total revenue of $114.7 million
•Reached 3.0% year-over-year quarterly revenue growth, despite the impact of COVID-19
•Reported quarterly GAAP net income of $6.7 million, or 5.9% of total revenue
•Realized quarterly adjusted EBITDA of $30.6 million, or 26.7% of total revenue
•Acquired Remote Patient Monitoring (“RPM”) assets from a subsidiary of Centene Corporation

President and CEO Commentary

Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented:

“We are pleased to announce that we achieved solid third quarter results with record revenue of $114.7 million and EBITDA of $30.6 million despite the external challenges facing the market at large. This is a testament to the dedication and commitment of the entire BioTelemetry team. All segments of the business contributed to this excellent Q3 rebound, posting 15.7% sequential growth. Cardiac monitoring volumes exited the quarter above pre-COVID levels, and our recurring cardiac revenue increased as a percentage of total revenue. Our Population Health business grew nicely as well, driven by the launch of the Centene partnership.

“Despite the numerous challenges posed by the pandemic, we remained focused on executing our strategy. We continued to augment our Artificial Intelligence capabilities, which are enhancing scalability and improving efficiencies across the enterprise. Telehealth and remote monitoring will continue to play an integral role in a post-COVID-19 marketplace. As one of the largest, fastest growing and most profitable connected health companies, we are perfectly positioned to capitalize on these opportunities. As such, we expect to outperform the market for years to come, with top-line growth of over 15% in 2021.”



beatlogoa111.jpg
Third Quarter Financial Results

Total revenue for the third quarter 2020 was $114.7 million compared to $111.3 million for the third quarter 2019, an increase of $3.4 million, or 3.0%.

Gross profit for the third quarter 2020 was $69.0 million, or 60.2% of total revenue, compared to $69.3 million, or 62.3% of total revenue, for the third quarter 2019.

On a GAAP basis, net income for the third quarter 2020 was $6.7 million, or $0.18 per diluted share, compared to net income of $8.3 million, or $0.23 per diluted share, for the third quarter 2019. The decline in net income was primarily due to increased fixed operating costs as we continue to invest in our anticipated growth, which has been affected by COVID-19.

On an adjusted basis1, net income for the third quarter 2020 was $16.5 million, or $0.45 per diluted share. This compares to adjusted net income of $18.8 million, or $0.52 per diluted share, for the third quarter 2019. The decline in non-GAAP adjusted net income was consistent with the change in GAAP net income. The details regarding adjusted net income are included in the reconciliation tables included in this release.

1 The Company believes that providing non-GAAP financial measures offers a meaningful representation of our performance, as we exclude expenses that are not necessary to support our ongoing business. We also make adjustments to facilitate year over year comparisons. Please refer to our “Reconciliation of GAAP to Non-GAAP Financial Measures” in this release for additional information.


Conference Call

BioTelemetry, Inc. will host an earnings conference call on Thursday, October 29, 2020, at 5:00 PM Eastern Time. The call will be webcast on the investor information page of our website, www.gobio.com. The call will be archived on our website for at least two weeks.

About BioTelemetry

BioTelemetry, Inc. is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing that serves both healthcare and clinical research customers. More information can be found at www.gobio.com.

Cautionary Statement Regarding Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in our future. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning. Examples of forward-looking statements include statements we make regarding the successful execution of our operating plan, including our ability to increase demand for our products and services, to grow our market share and to recover from the impacts of the COVID-19 pandemic and our expectations regarding revenue trends in our segments. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert or change any of these

beatlogoa111.jpg
expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things: our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business; our ability to educate physicians and continue to obtain prescriptions for our products and services; changes to insurance coverage and reimbursement levels by Medicare and commercial payors for our products and services; our ability to attract and retain talented executive management and sales personnel; the commercialization of new competitive products; acceptance of our new products and services, such as our mobile cardiac telemetry patch; the impact of the COVID-19 pandemic; the impact of the October 2019 information technology incident; our ability to obtain and maintain required regulatory approvals for our products, services and manufacturing facilities; changes in governmental regulations and legislation; adverse regulatory actions; our ability to obtain and maintain adequate protection of our intellectual property; interruptions or delays in the telecommunications systems and/or information technology systems that we use; our ability to successfully resolve outstanding legal proceedings; and the other factors that are described in “Part I; Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019, as well as the factors that are described in “Part II; Item 1A. Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.

We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by law.

Contact:     BioTelemetry, Inc.
Heather C. Getz
Executive Vice President, Chief Financial and Administrative Officer
(800) 908-7103
investorrelations@gobio.com


beatlogoa111.jpg
BioTelemetry, Inc.
Consolidated Statements of Operations
(unaudited)
Three Months EndedNine Months Ended
September 30,September 30,
(in thousands, except per share data)2020201920202019
Revenue
$114,655 $111,291 $317,093 $327,073 
Other revenue
— — 9,702 — 
Total revenue114,655 111,291 326,795 327,073 
Cost of revenue45,668 41,952 125,773 122,716 
Gross profit68,987 69,339 201,022 204,357 
Gross profit %60.2 %62.3 %61.5 %62.5 %
Operating expenses:
General and administrative
32,757 29,651 95,737 87,845 
Sales and marketing
11,652 12,572 35,619 37,807 
Credit loss expense
6,465 5,858 18,651 16,385 
Research and development
3,039 3,661 9,306 10,526 
Other charges
3,186 2,598 10,273 7,902 
Total operating expenses57,099 54,340 169,586 160,465 
Income from operations11,888 14,999 31,436 43,892 
Other expense:
Interest expense
(902)(2,338)(4,711)(7,358)
Loss on equity method investments
— (65)— (251)
Other non-operating expense, net(312)(845)(781)(1,813)
Total other expense, net(1,214)(3,248)(5,492)(9,422)
Income before income taxes10,674 11,751 25,944 34,470 
Provision for income taxes(3,960)(3,468)(9,840)(6,202)
Net income$6,714 $8,283 $16,104 $28,268 
Net income per common share:
Basic
$0.20 $0.24 $0.47 $0.83 
Diluted
$0.18 $0.23 $0.44 $0.78 
Weighted average number of common shares outstanding:
Basic
34,321 33,908 34,267 33,885 
Diluted
36,624 36,268 36,629 36,445 


beatlogoa111.jpg
BioTelemetry, Inc.
Condensed Consolidated Balance Sheets
September 30,
2020		December 31,
2019
(in thousands)
ASSETS(unaudited)
Current assets:
Cash and cash equivalents
$90,229 $68,614 
Healthcare accounts receivable, net
72,351 71,851 
Other accounts receivable, net
16,287 15,625 
Inventory
5,538 5,738 
Prepaid expenses and other current assets
5,976 6,505 
Total current assets190,381 168,333 
Property and equipment, net63,138 56,380 
Intangible assets, net129,023 129,596 
Goodwill305,591 301,321 
Deferred tax assets4,273 12,626 
Other assets44,689 17,464 
Total assets$737,095 $685,720 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
21,229 24,198 
Accrued liabilities
46,530 27,318 
Current portion of finance lease obligations
253 394 
Current portion of long-term debt
— 3,844 
Total current liabilities68,012 55,754 
Long-term portion of finance lease obligations194 289 
Long-term debt157,883 190,823 
Other long-term liabilities114,625 71,937 
Total liabilities340,714 318,803 
Total stockholders’ equity396,381 366,917 
Total liabilities and stockholders’ equity$737,095 $685,720 


beatlogoa111.jpg
BioTelemetry, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
Quarterly Non-GAAP Adjusted Net Income and Non-GAAP Adjusted Net Income Per Share
Three Months Ended
(unaudited)September 30, 2020
(in thousands, except per share data)Income from operationsIncome before income taxesNet incomeNet income per diluted share
GAAP$11,888 $10,674 $6,714 $0.18 
Non-GAAP adjustments:
Other charges (a)
3,186 3,186 3,186 0.09 
Acquisition amortization (b)
4,084 4,084 4,084 0.11 
Other expense adjustments (c)
— (6)(6)— 
Income tax effect of adjustments (d)
— — (2,414)(0.07)
Impact of NOL utilization (e)
— — 4,984 0.14 
Non-GAAP Adjusted$19,158 $17,938 $16,548 $0.45 

Three Months Ended
(unaudited)September 30, 2019
(in thousands, except per share data)Income from operationsIncome before income taxesNet incomeNet income per diluted share
GAAP$14,999 $11,751 $8,283 $0.23 
Non-GAAP adjustments:
Other charges (a)
2,598 2,598 2,598 0.07 
Acquisition amortization (b)
3,668 3,668 3,668 0.10 
Other expense adjustments (c)
— 787 787 0.02 
Income tax effect of adjustments (d)
— — (1,436)(0.04)
Impact of NOL utilization (e)
— — 4,903 0.14 
Non-GAAP Adjusted$21,265 $18,804 $18,803 $0.52 

a.In the third quarter 2020, other charges of $3.2 million were primarily due to a $1.2 million unfavorable change in the fair value of acquisition-related contingent consideration, $1.1 million for patent and other litigation and $0.9 million of integration and other non-recurring charges. In the third quarter 2019, other charges of $2.6 million were primarily due to $2.1 million for patent and other litigation and $0.4 million for integration and other non-recurring charges.

b.In the third quarter 2020 and 2019, we recognized $4.1 million and $3.7 million of expense, respectively, related to the amortization of acquisition-related intangible assets. We have excluded this amortization of acquisition-related intangible assets from non-GAAP adjusted net income due to the non-operational nature of the expense. This amortization was recorded as a component of general and administrative expense.

c.In the third quarter 2020, we had an unrealized foreign exchange gain of $0.1 million, offset partially by $0.1 million of interest expense related to a portion of the Geneva Healthcare deferred purchase consideration. In the third quarter 2019, we had an unrealized foreign exchange loss of $0.7 million and interest expense of $0.1 million related to a portion of the Geneva Healthcare deferred purchase consideration.

d.Represents the tax effect of the non-GAAP adjustments at the Company’s annual effective tax rate.

e.After giving effect to taxes at the estimated annual effective tax rate on the adjustments, the utilization of net operating loss carryforwards had a positive $5.0 million and $4.9 million impact on the third quarter 2020 and 2019, respectively.




beatlogoa111.jpg
BioTelemetry, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
Year-to-Date Non-GAAP Adjusted Net Income and Non-GAAP Adjusted Net Income Per Share
Nine Months Ended
(unaudited)September 30, 2020
(in thousands, except per share data)Income from operationsIncome before income taxesNet incomeNet income per diluted share*
GAAP$31,436 $25,944 $16,104 $0.44 
Non-GAAP adjustments:
Other charges (f)
10,273 10,273 10,273 0.28 
Acquisition amortization (g)
11,492 11,492 11,492 0.31 
Other expense adjustments (h)
— 1,159 1,159 0.03 
Income tax effect of adjustments (i)
— — (7,618)(0.21)
Impact of NOL utilization (j)
— — 14,381 0.39 
Non-GAAP Adjusted$53,201 $48,868 $45,791 $1.25 
* Total does not add due to rounding

Nine Months Ended
(unaudited)September 30, 2019
(in thousands, except per share data)Income from operationsIncome before income taxesNet incomeNet income per diluted share*
GAAP$43,892 $34,470 $28,268 $0.78 
Non-GAAP adjustments:
Other charges (f)
7,902 7,902 7,902 0.22 
Acquisition amortization (g)
10,742 10,742 10,742 0.29 
Other expense adjustments (h)
— 1,719 1,719 0.05 
Income tax effect of adjustments (i)
— — (4,146)(0.11)
Impact of NOL utilization (j)
— — 8,942 0.25 
Non-GAAP Adjusted$62,536 $54,833 $53,427 $1.47 
* Total does not add due to rounding

f.For the nine months ended September 30, 2020, other charges of $10.3 million were primarily due to $3.9 million for patent and other litigation, a $3.1 million unfavorable change in the fair value of acquisition-related contingent consideration, $1.4 million of acquisition and integration costs and $1.9 million of other non-recurring charges. For the nine months ended September 30, 2019, other charges of $7.9 million were primarily due to $5.8 million for patent and other litigation and $3.3 million for integration and restructuring activities related to our acquisitions, partially offset by a $1.7 million reduction in the fair value of acquisition-related contingent consideration.

g.For the nine months ended September 30, 2020 and 2019, we recognized $11.5 million and $10.7 million of expense, respectively, related to the amortization of acquisition-related intangible assets. We have excluded this amortization of acquisition-related intangible assets from non-GAAP adjusted net income due to the non-operational nature of the expense. This amortization was recorded as a component of general and administrative expense.

h.For the nine months ended September 30, 2020, we incurred $0.9 million of interest expense related to a portion of the Geneva Healthcare deferred purchase consideration and had an unrealized foreign exchange loss of $0.3 million. For the nine months ended September 30, 2019, we had an unrealized foreign exchange loss of $2.2 million and interest expense of $0.2 million related to a portion of the Geneva Healthcare deferred purchase consideration, partially offset by a $0.7 million gain associated with the termination of a former LifeWatch foreign pension plan.

i.Represents the tax effect of the non-GAAP adjustments at the Company’s annual effective tax rate.

j.After giving effect to taxes at the estimated annual effective tax rate on the adjustments, the utilization of net operating loss carryforwards items had a positive $14.4 million and $8.9 million impact for the nine months ended September 30, 2020 and 2019, respectively.



beatlogoa111.jpg
BioTelemetry, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
Quarterly and Year-to-Date Non-GAAP Adjusted EBITDA and EBITDA Margin

(unaudited)Three Months EndedNine Months Ended
September 30,September 30,
(in thousands)2020201920202019
Net income - GAAP$6,714 $8,283 $16,104 $28,268 
Provision for income taxes3,960 3,468 9,840 6,202 
Total other expense, net
1,214 3,248 5,492 9,422 
Other charges
3,186 2,598 10,273 7,902 
Depreciation and amortization expense
11,518 10,295 32,882 30,508 
Stock compensation expense
4,020 3,636 11,080 9,662 
Non-GAAP Adjusted EBITDA$30,612 $31,528 $85,671 $91,964 
GAAP Net income as a percentage of total revenue5.9 %7.4 %4.9 %8.6 %
Non-GAAP Adjusted EBITDA margin26.7 %28.3 %26.2 %28.1 %



Quarterly and Year-to-Date Non-GAAP Free Cash Flow

(unaudited)Three Months EndedNine Months Ended
September 30,September 30,
(in thousands)2020201920202019
Cash provided by operating activities$21,889 $16,472 $91,434 $52,602 
Capital expenditures(10,767)(7,594)(27,877)(23,686)
Non-GAAP Free Cash Flow$11,122 $8,878 $63,557 $28,916 


Use of Non-GAAP Financial Measures

In addition to the results prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), this press release also includes certain financial measures which have been adjusted and are not in accordance with generally accepted accounting principles (“Non-GAAP financial measures”). These Non-GAAP financial measures include adjusted income from operations, adjusted income before income taxes, adjusted net income, adjusted net income per diluted share, adjusted EBITDA and free cash flow. In accordance with Regulation G of the Securities and Exchange Commission, we have provided a reconciliation of these Non-GAAP financial measures with the most directly comparable financial measure calculated in accordance with GAAP.

These Non-GAAP financial measures are not intended to replace GAAP financial measures. They are presented as supplemental measures of our performance in an effort to provide our stakeholders better visibility into our ongoing operating results and to allow for comparability to prior periods as well as to other companies’ results. Management uses these Non-GAAP financial measures to assess the financial health of our ongoing operating performance. Management encourages our stakeholders to consider all of our financial measures and to not rely on any single financial measure to evaluate our performance.

Adjusted net income for the third quarter 2020 excludes other charges of $3.2 million, $4.1 million of amortization expense related to our acquisition-related intangible assets, $0.1 million of unrealized foreign currency gain, $0.1 million of interest expense related to a portion of the Geneva Healthcare

beatlogoa111.jpg
deferred purchase consideration, the tax effect of these adjustments, as well as the impact from the utilization of our net operating loss carryforwards. Adjusted net income for the third quarter 2019 excludes other charges of $2.6 million, $3.7 million of amortization expense related to acquisition-related intangible assets, $0.7 million of unrealized foreign currency loss, $0.1 million of interest expense related to a portion of the Geneva Healthcare contingent consideration, the tax effect of these adjustments, as well as the impact from the utilization of net operating loss carryforwards. By excluding expenses that are considered unnecessary to support the ongoing business, are nonrecurring in nature or which limit year over year comparability, we believe these Non-GAAP financial measures offer a meaningful representation of our ongoing operating performance. Included in these excluded items are transaction related expenses, primarily legal and professional fees, integration related expenses, primarily severance, patent and other litigation, amortization of acquired intangibles, costs related to the October 2019 information technology incident net of insurance proceeds, costs related to restructuring programs aimed at streamlining operations and reducing future expense, as well as other one-time items. These excluded charges are not part of the ongoing operations, and therefore, not reflective of our core operations. We view patent litigation as an extreme measure not typically required in our industry to protect a company’s intellectual property and which has not been common practice for us. We commenced patent litigation proceedings after we uncovered specific evidence of four distinct cases of misappropriation and infringement. We can choose to resolve the outstanding matters and terminate the expense at any time. We also included the income tax effect of these adjustments.

In addition to adjusted income from operations, adjusted income before income taxes, adjusted net income, adjusted net income per diluted share and free cash flow, we also present adjusted EBITDA. This Non-GAAP financial measure excludes income taxes, total other expense, net, other charges, depreciation and amortization and stock compensation expense. EBITDA is a widely accepted financial measure which we believe our stakeholders use to compare our ongoing financial performance to that of other companies. Adjusting our EBITDA for other charges and other one-time items is a meaningful financial measure as we believe it is an indication of our ongoing operations. In addition, we also add back stock-based compensation expense because it is non-cash in nature. Other companies may calculate adjusted EBITDA in a different manner.


 EX-101.SCH 3 beat-20201029.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 beat-20201029_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 beat-20201029_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 beat-20201029_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Title of 12(g) Security Title of 12(g) Security Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover [Abstract] Cover [Abstract] Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Central Index Key Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 beat-20201029_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 beat-20201029_g1.jpg begin 644 beat-20201029_g1.jpg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end GRAPHIC 9 beatlogoa111.jpg begin 644 beatlogoa111.jpg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end XML 10 beat-20201029_htm.xml IDEA: XBRL DOCUMENT 0001574774 2020-10-29 2020-10-29 BioTelemetry, Inc. 0001574774 8-K false 8-K 2020-10-29 BioTelemetry, Inc. DE 000-55039 46-2568498 1000 Cedar Hollow Road Malvern, PA 19355 610 729-7000 false false false false Common Stock, par value $0.001 per share BEAT NASDAQ false 2020-10-29 2020-10-29 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Document
Oct. 29, 2020
Cover [Abstract]  
Entity Central Index Key 0001574774
Title of 12(g) Security Common Stock, par value $0.001 per share
Entity Address, Address Line One 1000 Cedar Hollow Road
Entity Incorporation, State or Country Code DE
Document Type 8-K
Document Period End Date Oct. 29, 2020
Entity Registrant Name BioTelemetry, Inc.
Entity File Number 000-55039
Entity Tax Identification Number 46-2568498
Entity Address, City or Town Malvern,
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19355
City Area Code 610
Local Phone Number 729-7000
Written Communications false
Soliciting Material false
Trading Symbol BEAT
Security Exchange Name NASDAQ
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Document Sheet http://www.cardionet.com/role/CoverDocument Cover Document Cover 1 false false All Reports Book All Reports beat-20201029.htm beat-20201029.xsd beat-20201029_cal.xml beat-20201029_def.xml beat-20201029_lab.xml beat-20201029_pre.xml beat1029208kex991.htm beat-20201029_g1.jpg http://xbrl.sec.gov/dei/2019-01-31 true true JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "beat-20201029.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "beat-20201029_cal.xml" ] }, "definitionLink": { "local": [ "beat-20201029_def.xml" ] }, "inline": { "local": [ "beat-20201029.htm" ] }, "labelLink": { "local": [ "beat-20201029_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "beat-20201029_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "beat-20201029.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "beat", "nsuri": "http://www.cardionet.com/20201029", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "beat-20201029.htm", "contextRef": "i59f024ddc9ac4e1fbfa1eee0518c152e_D20201029-20201029", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12gTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Document", "role": "http://www.cardionet.com/role/CoverDocument", "shortName": "Cover Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "beat-20201029.htm", "contextRef": "i59f024ddc9ac4e1fbfa1eee0518c152e_D20201029-20201029", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12gTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security", "terseLabel": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardionet.com/role/CoverDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 19 0001574774-20-000104-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001574774-20-000104-xbrl.zip M4$L#!!0 ( ,6!75'FHIR1ZQ4 ,^3 1 8F5A="TR,#(P,3 R.2YH M=&WM/6M7XLJRW\^OZ,N^]QQG+1OR?C SGN4(NIEMPJ@X[/#%U4DZ$,B#G00% M?OVM3D!!8$1''1W=:^T1Z$YW=755=;VZ\NF_XS! ES1)_3CZ7.++7 G]=^_3 M_V#\]Y?38U2+G5%(HPP=))1DU$57?M9#;9>F ^0E<8C:<3+P+PG&^3,'\7"2 M^-U>A@1.X&XU)E7=]G1!4PC6>%W"DB2J6!=L#ZN>JW.>X%!=D7>[55>CDB:+ M,I8Y5\:2H$$WXKE8D&Q)()QK2[:\ZU:IP!.%V)KB>I+DN1XAA'J*XHFZP"N* M+;%I>QFL#E88I55_G'TN];)L6*U4KJZNRF,["!'E"VWDB4D2KTX M"4D&Z*@('"]C3L""4IH-XE+_>I!\@)0ZY6Y\68$&UEW''(]%?M9]:;XK,9^- MUW6],F9PS<=DX_CK01,X3@3XTHQ$#IWW!V@'/^C.FFV27G?WQYLZ\^+"VJ^A M2?UU8,/0?.5OX_C,Z=&0X-LP 7(QH&+IR3EJ[L*O=H.PZGAE<4MH8ZUYUVI MHN[G$HWP^5D)MID2=^]32#."V*.8_C/R+S^7#N(H ^+%K_/F5^%M ]&P@<,[+E.4'_5"E^_%0IAK9C=[+WR?4O49I- OJY MY/KI,""3:A1'% #PQU76D2;%1]]U:91_A'83."CQG6+^<79*O<\E7]8]3I!< MU]&)(U'>LSW"4THYF=<<7A;H16T.RC5,)121D$U-_6H] O@FI[3KIPRGF0DM M)>2[,+(K?I_8M?CR6#B]M$1CY/;KEYTCO=\,SR=&NRY8[89DAJ>A63L-.T>= MGM4^##I]2^CT#=GHUP4S;'#'HAE8TV%@] ][9GCH-VN=0:=_PG7@.>C?Z[0M MZ&=-FZW&V.QW?/-0XXZ%SL1J.XHQ/0W,OB,;K(]@3^?72N0)O<:3?D3K\KF.WOOGET&';"KV&GY?#-6M WVX;8 MK VN.FUC]LQWF$N..JUA']H#JQ^$S9K%PQBZ$5M@)S.FYU&P;O#5UI&;K M2V#QVO2X5<^,,VY\W-J_T%3"R2)1L<:)+I9X'<22Y'*8P%?)5F5)EKS2WA<_ M;M& FDEDUW4B)SRI\K2MC[]+A\ T28D:$0N'?]%)^_;?-= GRJF/.(#;LJQK^Z\FWLSC.X.EQ5K7C M.* D\DC SM^;C=Z'77;93A\&I/N^TW?M]-CPV2[GNSTQNA>:IVBVR#M8DU4/ M2RHPLP:R&G.V)G@Z1QS%<4M[A_O'9_65[:XLG\<)]6A"07-)UZ@13+VHIKF& M P2!;.QY\UE_.F2N:NMNE:6>M9KF+JJ5#\I(X&1)?T%@OVJ:.6R>&C-0WX)"/;Y6 MLUI?_69KP!MA?0+JU-BL-7A0L_IF#50?H2Z9T[IH3 >BV7) 9?HNN7]^#3I" M<&GWX[$1-N1FZWQBM>!OK]]*S0X4,U 1>N*1LN!.1W>Y#79^ F=&+T3 M^5U@"EL1.1'&">'G' M_5#\$'LHZU'6:93XF0\@U,=.#Y1GBO:=#$$SKXO2:R>C93U-?Q;%X/9.K0>< M*<4,RZ=T&"<9VIE_IP348IIFB%XR+WV2-U/W0Q4]J9WKPO0AC-ASR60",-!H MG13^EBOO]4*E?UOB&.8] 7@MT:R=3(U^8W*AD+;]IOSSS\T!$[-5?S0?^\M74';J M8P('(:, )I>3ZYU')$7ID#K,E>(B/T)^EB(X.D%,)Q]>_++N=6#*O\ZOH>ME ME5,?XM80^;(J25NY->[7)HOB@Y[\O8!5[N,PVN0=FCMXX+QA+IY5JEI#&,_O M1.">Y$Q94+M8A)TY4S,Z3.)+)FJ6]:[BT 'Y&2>@!N8A]C/6^R >12!:#V+W M=9Y!1>S!K)F#3LL-C;XCFL+7@7ED289P&%KA]X%1VY>L$,ZI\$0PC\YOQ1YB MSA!.85QK8DX=T0H!QGYW:K4[?J=]CZ,$79J%M?YKET=M_:OHTPB\41= M)C)6>4W"DNVJ<'3I*I85JE)7=%2!!Z6M1@-R!4KP:NQA)C9GY/\#REYR7;XS MP5V*U:$?4!@=-.5W@MZ"H!LW20^"PTF.+6-7\Y@50B5,>%7#Q)8H8%H@MJCF MT2 LRYRHOU/TFKQ/KLG;L3T%]$ /BYX-]H;K\M@6 M10=[@FISMB K1.)*>Y*"X:,FZ=H/Z?LU*B4K6GQ.O3NY&L!<>G'6HPGJCQ(_ M=?W;:4VH M.%?>+A*63UEDQN4/JX2_,6_@5?IEM%>9;R((95T6'MTK\53#EN4'.F9^-*JD MEODM@5TKL)67S:&_2-?>=]V$INGLSS$ P+]B/=LX^NX7N9AUL5/K3LV:(YOM M.NC.UJ19J\M6:S"V^@.N4]N_K6=?==J-(A>SY0Z:-8,SIP/>:C5$L]^0C%;0 M:[8 _M;IP#A<]HOPMD9DW@.[T55T+ FNC36! X-2DVR>J+;"LTP#V$X.'5"7 M).A/$!\QHP[B/H]-N9H+]B!E)K_,]/98XP ^-A,@D.B=,>YBC/$B8^BJ(]B. MX&!.YF0L.;J(-9F*F!,\XA*/V-232WL&"8"DHMW-8:X'J5H!]59HM5 !?A=R MO;_8;/++"_Q< *0<#P/ M*HRD *HE3@7RY@C%FBZIG,V!=L."/+PNRO+]_84O7 /?X!::417+9!@F(#'] M(0D0'5-GE/F7+,$![&>:OETGP@YP&F*L]AB^@W572%Z@R^$FF>G??V@"KWY, M448#.NS%$451[E7:99ZV8,1V$9&$$MAEEU:OM9I?D=2_\X02F&G)^[#,5RMS M?R*]L74RO=!LHC@:* (.T5TLR:Z#=8VZV%544:2R9'NV6MI3^)4$Q@^/GYUZ MLRO',4B(;XPJ7W$([6=VQA O=#BU>$ ?2S$%C0U,=4Q47L." /LB.@IU-+NT MIP(&@6NVR"_]H:#Z->+HH$>=09Z43H9@ < QQ4)<=CQ&-F6N!K_(6#\$BZ%P MEFKX+^3Y 9--?@J"*J.12UV6^I[ZX2C(2$3C41I,4$HR/_4F^>.S!V(;Y&_A M,)YEPB\D^(U@G 21:#)O\W)G!WN.F28^BS"EU?OA]-:9B)EIQUR7U[Y;/V)^ M["HN?MO^2-@'/ 7H//*9:$;&V0O+H+UMX+$+U38!=&:PLXM-5SB:I)6',F_?4^ MQ/,8@8O5?Y]'1U@/TXR6@'P7B0D-%V['G(X"6@ J"?*,XV]=B&'W8'9X%1T< MGB*PCLO0<7-^[SM?;^#KLSCP'4!HU#5 GK-%O3VFEB\TWO,XRGF8$N!G21$LI.:E<#(K^MX;U,Y/KBZHI&A4!DQZ<#H#=\LV)M36,*]Q MFNPJ/*^I_#MW_Q F("CL+%#4=F6_UF6;Z3IB"9O MFO''%[JC.=019*S# 8XE3^>Q+FD4VYXDV51S@?>]=\9_"L87 =T[SCT8?_; M9L9?O=:ZD&*EW(?C'U?MN3%("A<%3:B[A)7917_$,\$V=UG ^E<]%"_QEI\F MBP^ZY2>6.?[Q\[/ S!-5[?&'%@;?7OG9S=J,ZWW@ZE]<@ MOZYZ/OQR(^2>-'W]F9"S/MKXA,&2V7$QX85NSF*O4BN;I0[T]R7CZ&N_<_0U M,-JL[Y>@<]00C-":--L-T,[VQ^RY9OOD=NK Q*AUKZS0'%CA^9AI<,;1]X'5 MMR:=?D.V^B?07F?:G-RYE>[%+LTIGB1B'10[YGQ5X9/-8<5178W8(A%D4MIC M>C 0[%D6.X-=-"0)NB3!B*+_9;G1/!JR^HR]G[L_NC4AA[[K!O3W(^29B"PD MY#L5;T'%-_E=A.>HK1,%$\[1L"2Y.M85D6!=E7E)$F05=J&T]Z6^WWJGT)^U ME]D)MIJL.!?#6XBOKG93(DG4Y>E;1%9Q1*C9%U5'.QQG.-1AC!%7K=F(03& MR6BU(-Q-'3@1[;".ZL<\##;O[.=E;X:L[ V[B;I@G LV%M8,N*["W/7(S$:_ M>6YA[/)K2%ZH;\#X0WP\OX&OL$AEG2/E*,?)08&25RD%?\I-.+FP5=GE=$W! MLF/;6-(X >OLM06JXRBBRBD*<;C';.SQWR'+ISD5I6D:_ M5M)9>=N]54 MW4G7^C)=ZT\0,]BN#' CHR$2RIR T"E-1T&6)_XW06+-@BH@ M=]#AM4@ZB$%$LH9556OS0A?,OOXHS7QOLA0F%9\B8K)=:=UF]%XK=TGI$>=* MCS5MC(WIE]"<=D'I<5@M6S#?ZIS9/@R;+7BN]G70;+,J/=8MI6?8A_FGQI$E M-FL-V9PZ'"A,LM4ZX:VV)9M]BS/"$QE,.H!NJ5;NQ.@/A,>LE;N+5JN+@MF3 MCN#T)'"0LELN(-(0P\<',()S.N8(5';TR(G!F$N\QS#PC*BZ'FT]A,2\K1 MSS*N:<86 ;H0S#$KENHL3Y8R)!:S 4KW@4>'U_G6R[N8)WA8Z1S- MQ?;H>IE?([ZV?&,,MTZX,Q,'@]A(B)-5TU$(,G#R\25+?+W,\4]C+6PG>.^M MA#XJ"F[.L_QR,)/!Q4$WHY/T/J?;4A:0KA2:QU(:D/XYQ;(KC@"BMMAO_@*Z\M!1Q[^O4\,?2NKR\ M(R_A$UE[\-,"IQ]_.8#HYAV%S"81.&U Q[K.EWL9T!O3?SY5R&T+^%&8X$D( MXWW['W/[ORUIS&ZNWL_,*71C2:TEC]=0&'(;W+'R5-*S2?_-M/TK5GX0 RCH M&P$KL,'V!"B7E76HD8R@O$CD#K-D769!,>L)S"]F9C5R!0JQ%[DC=^:VV*;^ MP6.XTU@YL9?YOJ;UUL59X\C<;YV?UK@(2Y>AV+3'@D\9ORS@7(A-NO #/A1 M!,_DPY%1UHL36)R[K>'P;+&#AZ^81_"^80;/F]MFXS:/#_K%XVK/" M<0"P<58_" V& ]^ZY_V 1[V-@?? 'B:M<'8;'_UC;XES9^!N48=X5SIM$[] M9OL[/ .P'QWZYI$9&E/V-H?&Q.J?2,U6G;?"QL3L]SQCPEW-\U+-BJBT:M\9@AI:>PF5^-Z?!E4MUH-"D;,A;N] (@]KYRU[5@?# S)'GT91^;T9B*=Z;6>D5+N@6;^RB@V_[#[F3 M]4XZ=V$Z=]4_&>ULM#!X[9?9%_7KTJ/??8[N M^\[?^6PSN=B6!7H J9C@4R=P?0)YVTV&WJ'O!][] MI_E7&^JTL07CZU[T-I5%%S_T&G=*%'3AJ2E +SPCDIHR@G8S47J-WL /8P<1 MK25+:PW70I97D).Z,,":?Z])P7(&U-2\@*:JO8 G;DWD$O1G4H*J2 9OR3H; M(-14@Y65D!KQH]BV'$$>@7?7F(B/:ML2+Y;#QN!GB(,3#P-TJZGAO M2MLG8EQIPC,X);?YPAWN3\QAO[:GS:'#G3X'2Z8@.YV!F,J1&1=$H6D'=;Y]E^.-(N]I40F4E1 M_**WO$J*"J1FH)[N)4NPDI!/G69'X:Z#OV6D<,U,NI!G"?K+T;@] \GJPLJ= M[_5T#/JQ,@S*+$D!NPK]S?(IY*?*-Q#&V7^AOB#IJ>H-!(I_7G@EX53A!J+, MY?$[;=_@;XP?,3IU+H7Y$>@N> (=@@[H:@7T"Y_9\:'L%MR&O (\."7>C.MOKZ.PUMB5M3USO?ZA MN_M^ MLE7MJ[$OP0K@R'8+_?;#7K,I^Z,]] 7K7O\XY]C7Z]MYZ-$+&*OT6$=IG$0( M1J&E&@]U]/#M$RZCV\UJM?Z \=/=?H?NM7@>8'1H:X [D&A2KD./$NP1M48/ MZ%&;HWKA&&_"3UM]>C7JT#E$$YK\OFLJUK2,EM<9-3GL@F;XH@VJOQ6/E/PRV@Y7"C M#64==\Y(Y:+C7$]215<.IAW.O M,]#64;.\ ^R'FR:4>>>K2P'R*XC@O7CNP[EW2_TFXTW?D0EF!Z,$Z8W6Y&+^ MF]5W4$L#!!0 ( ,6!75&%9/NG"0( (T& 5 8F5A="TR,#(P,3 R M.5]D968N>&ULK91!;]HP&(;O_ HON\XX<1*2(*#2F"9-8A>ZJKU-COV96"0. MNH%0]]#H'DME%Y-O8<_ M/W'JWW'/"Z@8 M5KJQ3//_![CCA3UN/+6)R>NBBS9JW'3[%S5GMOL\GY: /DRT(]S'<#N% XK# M8+AOA#<;(/1Z<\QP4Y>P!(D.KP_+7Y>F2ELB5$4.&<+*TAEW!/NR@:G7J&I3 M0C]7&) ?VOL8]\>PEWQJV2,Z,<-6!'?*Z(IW? MO':-N&^PG_OEK@'CMJL&/LTZD7/ B8C[XDJKMHDLW/! :<^\0@GV%K0 X2$E MIIY**!U)"3Y/$ADE7&2!B'@N:-F^! !U=8 + " \'"\##U+ P114'YZ_?/P70OO,? M]3]?VN0 [G_VW_U7_:\+*S0; *IBT#\ >8#@UBW\6W@$^/CXMV\3$!)3DA 3 M$1'?NTM!1DE/"V:@IZ6C>\#"Q_Z B8>9CHY#E)/GH8"PL#"875Q:3%"*3TA8 M\,\D6+=OWR8F(J8A(:$19*1C%/S?OM = #D!$(B=@X/%!&"38^&08Z%[ ##F M2?&P_KK^\\FQ<7#Q;N$3W"8DPA#4W0&PL7!PL'%Q\/!P,2QB^6/& 5QRO+N, M K*W*+2?XS,Y4PH&QN40,,M5=8)T)N L0B]<@FX34E'3W*-E96/GX.02%GDD M*B8N(?]$05%)64555T_?P-#(&&II9?W2YI6MG:N;NX>GE[?/N^"0T+#W'\+C M$Q*3DE,^IJ;EYN47?"XL*BZIKJFM^UK?T-C4U=W3V]<_,#@T.34],SOW?7YA M;7UC\^?6]L[N'N+XY/3L_.+RZOH/7U@ #M8_K_]/OL@Q?&'CXN+@XO_A"PO; M\P\!.2X>H\"MN[+:^,^=*9@$ PDHY>)RJCIO,POIP$$O7"8(J5B$UU@1?UC[ MB[/_-<:"_H\X^T_&_L77 D",44QL5QFH;QL89'\:*!WAN,1VR]_' 6_&S1 5-^#!DZZ M5=% ^Y^AB7_KF?%]Q&?U-^*C@JS\/R/3XT@'!*&8D+'M)']N7N&>T>2Y"ZF5 M[Q+HYP*XKY7I;%(:.FMRB_V6EF3OGKCV9?F1&$FS]P_?96\'X@&_-[:Y^W%HZQA MNBG[XTL*/\9/F[CCQEL\;8N;?BRSSSO<[KBJC@QHC:ES?QLO,0OB'$VOG8E. MTW^N;TZZ492_+5QW*U"!4@M+@7(JRU0+IZB"7P=Q;7N=U)M=Y2V5\MW$ZUY) M%KQZ"A58B09@"FX\O 85<<,\;PB:Q>EO0!VPKF'-ZUOM-S>4_ZK-DM8L,%V? M@Z^B4>&KD#7KPAL<, H5_A\U"TR-X6[U,N/9+\C)WV>X#&!AJ2=77' +I^^* M9\&_)Y8/K]-IEC=:()E7/N+X7,R68;JMI:U "?Q5E.W!/;1('[PR5Q6*X2V9 MCN+(4_9KW4C3+"XV5RW#E]] J=G[ OMI=N9*]Q6)0!Q+LJ!">75)@3Y5U1V. MW'!Y0H[)I0I,MUZ\&SV8L^-'!U]Q<:^,64=X5K)+S@Y.Y['$.. XT_2(!.*-TE5FS\JH/;R-.?\72"E^<5-:R M6A@*>"%Y$-!X7J'982[3NW]W$7NK9W[UR@1F[69DST&G$F;I CE+U>O548]XB$%;D>T R'T\MS$ M=Q1E00+%'*J#"3J$=D?N55OV%9=Y%BFT>FP$^(1?BKJB.ZHV(*JLTTC+[!B9 M2ZE8FZR'W(7KA@5NF6SJYGU=RV1D)B4*\71R>2[7SV#0\C7==7&'SQ%&45&? M5ZZ\@"HIMS-ZGSF78@8-:YH?]18M)QF5F@V5MGFV 0]#Z8T?Q(]J M7:;><69D"+L./V26I>4B#7\H:,L8RJ'%HEWV2H*K D#BJ02:"J5GY>SHY.=4 M:A7DAK_3R@WGP")A+-A7"P>V*_WH\U:6!MU%FJ^JZ1J-"09+T \< =RTF7Q M^]J^J)>/6P&::Z CZ,99[TGILH(9LOB/(9Q>%,V4L#^C \^&>^Q0:;(?W-4\ M)GQ3AA$-##1EG2W!RM_(E2WII8LCA#G[(M.4(*MC9+;7,^73*57-PBYX9A6* MM[@+T4 PF2P:R+R+!E:FC%=(@-^D.6C + 4-R%9L@XS2ZICU\P>[M NY!-XP MI_PAEOLGL8[L:A3I[7C]>I6#RKB!W?B]-F72K^J?HK-))C3T.A=6I8C+* MU.M9Q3GYHL_;^VII?-@3RB2\ ..NJ5)/M%NSC,08,K!BJN5<8BOCH5UBO\H]FPP$29P8AA$Q>GMT=DWGA9\+FE@Y/ M$P;!D\T!=5M@E1I*MIL0,$Z2X@# M<_6U#!QMQ'9XZN>7<;2.$N>KISCB'=?7!K4S&?.\*_*+;;3&TC'=-VSB6,2( MU(?^]R+(MLVLE1R)/>!*N/*OG;/U&=XZ<4&_';G$C7F-]<#@X5YV_MIO4!-, MU;E*GZP_'/I+S#IVC]U3V:#GVO*-T M:7WX !JA0%M=7 M$5>SU!V55[?V(6<+D!O<&=;#Q>2SJGW+U5,]5/'.'KIPYAB&#E_,W4RM[!IGD;4Q+7DY((0/ M=(Q9)I?. ^#TL]MB V.2_E&DG*79K?4RH;EYX0I)5$^>#0S=,V(@D.ZO4S%. M! WXR:.!.'?(?A,:@.[OQUZ&H0&F/=B<.ZKN*_BRZDP< >M(R=%=*T1Z[8'/ MYF&GM(>E(9>V:(!!(NS&P^+F5G-)F04B7X/HDIQ0E41G1H1#.$/&I#FTZ\&J MI^4.-VZZA]+3_-R*07['-[_>C,P)\6A7&EB:^E_T^!I]+$_*3X@>/:B#);G4 M4^QE/IQ]Q)7,GA0)3A8Y$YG?#0"FRO,,VI;<'XD/,N*/PZ(\?G/I)>VU^C)X MUE<:+R2_QWB\D"3?3S=!Q#Z.D-$Z833P/EEWX(.OPWEO@Z#_3S!T689F@O"- MQ&N:$"\="GSA3QVJVMKW2Z-=6,6(G-(-ZJV[:.4H8"9>,# MU8K=C(F;M&DMOG)SCE)")<(4I67WOW[#@9$U@/:=-%+(6:K$7BW)&U =3LQW7;R&O'>JBPY@64Z^[W8)7,1F[4(E M(-T_K!02]"V%,_SRQ?3/QWQV4KJN:=DZ/YML+ F9-#[/*4@7UW-VIQ855!*Q M03#=>7*T55,TXW(L4K+PZS9O7*6OWS/O%L%QW&UI1VOBK*[G8-BU2 MXG,6R<_FE^+4$/E%_:$UV][YS'#;TCQ)TUG&\=,-3T&AJ$Z083%;]GB+[*U& M2]8%17B9@W9PL','9+:ZC0EC#FM;-FX8(>7>T]",$1_=W?$JHY>) YU>_!V MX1L>P5+-].+MN=ZA) ?#JAUH9(EUDBV"X\ CIO M28MF;>M>^G8X#Q*:VG4./D^JQ[^OU.IN 8_8R;1(N4F_M9SEF356_@@^?@%M MB._5OTBH%G ;>_^(6H?%L$JZM/Y^#'=6N?LNEQIMR^M[1E;D R+;J =P)GE' MUME$&A!N73/=IB]MWNH8!>SER+EH==RKCD0/B%/T2LQ)+^=X\,:8TB&A5UIB MX:#%D33#^?ERUWQA4^J+#SXUM!O\;Y<=_'5]>-10MMJ,-BZBK M"Z4<2OY!;)9(NKTRA]DG,KA3O,PD?J&'+N)\ =JGX VY M5$1^VEIOSE9_DAF7+^7D!HF:F7IGR#>GEA M3^,JY7UE9.E;!'^(];BQPT&^9PWO14UHY#D:.)N*=#K+XIH(U^D9-YWT5"HG MK:T;\N+N(2LUJJN;PO%T[ 8?55J:&=C'Y].Q#HU>ZX.4.1\(APF#R__X4MUY MJJG75CV;+XVQ^CI\R7PXI]Q9AT*@M;:R@^G0]@CA;_21+L-;ZC%GVL>PZYF1 M,0079ILT3&D;UJ>S0PI>7OIV7DAT_#9;C *5?@J%!%C "F>;(S3Q=SS>4QKE M91TIJU'<<)?WDZFI<->$"_;,SDHPI[Y;?_J[/ZN0F1_&I0'3-I.)62\7,GX6 MJZH#N_K)?BO^HG.!?O$U27Q/?UZ/1]P-=R""+,2A169]BUH0^NYX2.;49@4\ MFA;-4-],0O,)(2R]ZSMP5C4FS) TZ"7:\ZU4;M;PMVGW#5)=M-Z=D4V>48C:D$N8I42B.@$ZUR[9+@QH_(RT$/%SLX" M>\#=CKM[8NRGE!ZC[VT"NUWW&?GX:]44[QMHE\?#GJIDXI98H-0"7EU.IBZQ M47F1@K3S9^],XUV.L7'F(;5*IO1@DA-4QIT9NWQ\"KY:XP>?3D^KK#D?9Z+#_(?/4BR,CJ@RW44L#1,'GA-+[MWFW8BN61ALZOKD)FK(\K#T64YZV M2A;#;LGK,V+@:QS$DGVZO0/IRZC!@Y!6'4^GE147)F,*4V\4)[^N<#XBHH9:-?>-I-Z9/ M+RJ^V2J!'A6(6G\?G&UY;I^S1V0K?'>@5[Z&7X%N]JQ\Q#-Y8E'N1UZY MR*#?XPG4W.>*G+NH\\6UACV,)ZP,CUC;JMR&#G]6GH_GSY3*+/+5:]).8O Z MK.\)!Y')%]&]!4^:)MKU\A6RT97M#ZK]DPCDJ++^<:$:A M@6/6>33P70%R:IJT 54,J]P;'U@0R=A$]'4H/_,COA'DG@_X-^P(PV!'-+"_ M!HLKUZWEDS>,VX; 0RXW4(&TA3=(,%(?_+>6/T21T]?PNU_AR-_[Y2&!2+/: MEFNJ["&)Y&[8KYDS/DX!I3K_=XF7J*W1]2%-KL,%>\]?-8SRUX'FG?#]=;XP M1UP)WF^14).JA80^5[IRU(34N[-*@_8IGCK)E_5MM:%;;#3<7+KENA88H?&/%Z MH2*+[X,OHV^Z" E1U<_UW6O:,ZPLZ&"I)%7&*/X&&)EP!=M?Y]\VLL!NW[Q? MAO&]K]# *85).PT&.F<-HP$+M9]'S?5W:I_)*,,G6D!_M/11X: MQOZHBH.G=W%6V@O:>19O&1O%U8HRJ?B3?=F_G!OGDFXVO 1IP2JLCDE; M;1GU5[&\ 2JFL#\M?7_0+XZ)"0/?^QA^\'L!#_:(;&.N"N8:09DM<*PF3+0S MA,$KWXB$;=!+B_#CV\U6-"[9_?3_2!PS35C4+"#L KG5(K>0%;8UN1W;,DN, M327U,68)V0C:=3^9ZTSO?]>W1?F[WJ B']89YO5A^VQM-P9;RWRF:5]5&R^&3Z&DW,FN?[5?DWCJ=R$Q M."N&7A[5S(]Z9S9CP'\YR8Z')'AO/Q+ :!?Z1E42EWTX4/[AF>5DJWB3882= M*TL;3T.RBU^.A^9?)PV/>IU6 MQB7:YZ$6.*,)ZRKSDYZ.O':;%7QDOE2="NF 7:^BW-+J(VOIY56;:D^L1ZJJ M(_M\-L*WV\ :$Y7T!BYYT5HRK#I-.S_43%&F))7(ZN,YJJZP$LL &^ M850S^ 9WSGZAH?(#^)BH&H/F^C%AL\BW$)2PQH@CG,7L$O8/T/<2E32=T.NR M0H81M9'%]:^9:0SL#L=$L7%>CFM/UMJ8]F) ^;1N;U#-VRF9)9(!;%FK)*!G M56\T]$=J[C*SN,GV[X=O(=T%TGL-R>.=Z5Z]BWX;B09TS?3#HMPDN>_[6K+D M#7TPQ!:*##2+#]X(TPY:7(U4BBZI2NXJ;)=TW[HX2MIVMM&IZ@ >6OMYXP%^/$MTO_K!"(RF3E_"JXY'?>M>A Y76]VZXG[Y^HW,S\H7"(3W& M,NGR T90DW$+:YH[]BEPMOB4A>;%H>:\6JW'4C]C- =>-L$P&LM3 =M>@Y0; M7+Y^]YOO#'%R/Y("#6#A7Z8N[ M7\JLL")K7?+CS.-HS>6B?ASFPBT27\9=\^<(,$H^N;\= ]YK: \[!DN^2B'[ M.">:10/ MBJ.!5^S]XCK>3SB)3@VSIA%OF^ 4M<&9J2D"XO QYVP)+LY$5M7 M]:_N6D$APK%9T-(BXW[8-W6PC3^D-_:) M%RF4FJ'5&6,3FTB\L?W:[P!T9 =,$,2)>?MRLT!30]O.ZO!*,^M\DHCDS-1I M_A=OA63L6)[..OT_M$[[K[Z5^K]+S4:&7O;>OM=@) M^M;<+1@:U4<#5MV&K4'&V[?+5BYV)F%=_CG@/W=?"_O2EOX*FWTE8L/BI)O? M1H6075"AFCP"'RC">F!5-[YD M-P1SA7]OSWKQ;_ KVG^$82&C3S!6ZYC?MOWL (P*XM:H\8-@E.D\'0V83Z"! M':;:TC08A<2N']&XO(JJ+9>J3:S7'$IQN"VK>^YFPDSSK;!PT,A> I]U.A/O M4HHTC"+M)]).:'VX:H\2MI';:J@9^*:,=TT[))I52R:HE4Y!B98\?,_;R$[5 M*W7PU#I6O/!%K,[<)Y\>W6XZ>(L.WZ8[5\?%K18_[V5*A(7_%U5ER,I[#(HN MG;]?/]O@^%Y",\.6JO#.U>H5ZT9)9AB\HHSE0!2_1LQY^D=8;31"4LU;QTO' M: 3:W+B5^WJ8KP&&C#Z;9XV>_>1U=>?TN.GR/9R#]-9T+/=;[T9PB4EL;J/ M?0SI-V[T%FS5K.^_,$D8&%.@APD%FKVC(TX[)GFQI4EQ66EUS\H;XQ=^BW=" MYA#E\,2K$K-?T7[N2K1^I1YN:(#T-(MK]HV&PM5G2::Q"WQ8#QK@.BRI2RKS M,(C]\42 3AD$(ZPQFDG_M!BUHZ-77!1"J6V<_O?L=!&2$+,V,N48GWH;&65^ MN8)9 ;.LFV!=-* PJ!> A\$B8$,,K@I&*=;^QKW)FWV57U V]%=&? 2!%PQ- M":LC$M>CV0J,1AC+LS_5F9B_V6+Z$8BJ_LWK@U\^Q\2 >I9-VFM W,9R.?C M*SKP^!6YD(*IS1,:?@N>2-%32,A3^@+G84N+M:0A4Z3,I.H=OX:%1PS! J Y MPP](*H2$K# *W)BD]]1OWS*3"'8WIJ@3+&\^?5M8W3C(AS0W/CG_N;$Y:Z,) MA&@OA?@Q^<+ (AIHZ]R6!)@>;4: M -I/TO5\$=UI&M8#N:+61357GE6T_1=08!B&XO%_ZOR_G $B;S+\L&)2ZI6[ MONS!$>/1^9'T\4LQ2#+W#Q)O2'3M137B=J-L<".V@J,B/:ROKJ/=O[\QU))Z MH.#[#GZW+\78C\/&EC:;7^Z7,3 MT"<$*(^=ZEM.2(Y8,8LS!%[^NGT;M7]L <]#@PLQ"\7C$P.E.CA]XD?=93_;F[@*5_P3340 M2TGV$,-.?UX$M7/R/G?-G["Y'SN^/YOH[H/K=$HYDUQ496KX7Q,[!S%_0P%3 M?[+6C%$HW(CV?_CXO9GI:T/^?^5YS%2**I$JU*$H8DU&1(^Y1?@A$3$WU\/K M9S@W]MEUE[Z6KO:4^_XN5 JD#ZG;U[20"E^8U,P4#+ED0U"M[>6OO:@-3)9H MH,JN(H6#T3]]P;MF-<4B#LS?N@.8712WEUH0O1J?YDI M$U&,-5Y2$M=LH3PM/P, M@0:JRXW^_4-IS;K^8V?$(2L885/*=]SZT)V#,"A[3?<6(#_Q; MH%)#FL0[I@=V16H"FR.[^3AG3G2YPN:T!>Z\RFO]*]U^#C[KA"39&CAB_GX3 MZSD:,*6X,DARU5RW,8,$X@F?%>IJ0N/''EA<<3"CNC"AD:)AY47EWYL5BS;? M3Z46VVVO/Z7TB$5X.5L!67QN+&0:]DGP^M W+;(D@VE[KY:I<>R>P97H T); MJ7MH8>>?PSSM\$=W5&$MXJ M%-&,8E(E@8TDTR=O_LR''?&WD2Y<\..$[&G1 M)R^>@SY$?J[UH0W_N4*Q&96_Y!0U_;SWY! M3IG-,S!-.EC/\?3Y;QD(8L/D648I,W$WE/CHWQPK=W=Y%NGNXC;5 .1.;AWW M/_TL"2LOJ\K38_Y[L($5US/-3>[9=32@EW48?JSYMRZ=K,,Y!^Y+)RDD.Z+$ M)X:R-BBY(>:)O);9#R5W6]Z6/(&! K*-7J-\IN"EGDF[$<0/3FMX97CXX 5C MPG LS)L,MFD_E^>T5U;(U?T@^JP+^612-%\BW_X"YLF'[]!_LH$HY\>V0P,. M$ZAAYI?V%HG;Q;H#D"EXQ:+2D6U)Q.?MC-" OIK\!"8#D:1' MF3#=F*Y69J6I*;7)@U]36;SB,H6-R-WA"SU*GP&G&Q1[>CY,\#K<_0'=Y-SM MG9!_>ZO;.!9LSC)1RRNDHZZK'313D&%,]31(D<2'K ="N.35WEUE!-6D%%)P MJ0E-$1,SH-FXV3NA@"OUX**!?E1&UD46DMNH=N.E?.N8'L;4A:V!K\F@L!4E M),=?+?Y_M+@Q$+Z?+,8X7WNNC\+.H?'\@=?SUB?N:I3W4"!, M8$ H_GR1;S3!\'(^KY.(+\'6V9?_9=P3S"9")?U,N4YNWSCP$;'R+4VY>AY$ M'ASI2]H]G7;Z3735/4BPK;!DT73U..Y!E.:Z"PQZ:D;=W:04=C!":Y9HL!=P MPL^#!@SV;(L5(01V(UE87G+\!*]>+'U4\95AV-(>K\\^!\U, GB\5D-B9)&P M8\V?&(SQOCWCN=\?..)0@P;,\M# N+I'FS3\8"SI'I\#B,;,\J7H^DW24HM' M *.SHUL[1Q/.A0NL-:;)W]>PT-SXAP54Q=X=UU668P$QT&C <+:)8KSDI)P4 MZ0OT8<+/JEFT3MDINZ6TD38A?/IBSZ>U_*S@5,Y$KK,72! MF>5$Z2['H,VS[ #W$[\5$J1MH=K[TUV33-I9I^Y3<7!LC@S8:T4KX763^\1% MIA,^2NK5IN&B>LVTE#'"1F5B/7Y%-BH$Y]N [R*?' M(X=[QU3-S=)W?$CG3\'07T@(7-%EEZW9[_V[!$?[A*P7V^#";?/&@ETJ6I%( M#Q__:EEL8CSMN<7,[7V%Z8 [,S%3KWE/6V66^R8?)L,5R?&_H.H<$K"3:SBX M_^O;I3F&I-'+X:=-,VZR))]>J%#I^Z?B/+"9K++W_\86NFU5,]]4>6-\/%,.A6V\:*GN:6#*8ZQ3GG$?9,0MY?ZI\UBI0/DIE M?94+4^Q]K6VLJ,&WL^RL:UJ&*!?2G99B+VV2L@(W\Q '7-+W7\X5[,JP3;F_ M2LIIT(^-MG0-I;RQ[YZEG99TL.QY%Y)$2@.+9PGV+J8CM6]K3L0,U\JO9CZN&AMA'Q+WP>&.&)YJ52 MBU9V=M O_J<\\_C'(B^&.Z"M(X$5N![99R]^? S 0=H94,7/ZG*N[ZM 'W+; MHQB;$:R3)KT4^?=ZG/AY^JM$5BZ5GB0H3 YI](]]/'+'#Y$)RA]OX2WY^7G#/5S7&@/&_O7HZ^.::R3M>(7(@0U-N M]8$E6GVE992@$[_ )BP^2F^^@HL4(VM\3.AT166(:JH_K:BHDN+/'\O=);)U MVCEJ_9@X*H[D=OA)E!U?@T3NWZ*VKT>JQ!SM;954 M>"-;J7NO'4II2P=X#WV$7>A?@D'19;%LI9-S5&/VB) M-4FX-/SDE=XG:-=95O9.X97&;10G['H&5!\D\F,05/B!";R2V@T>3S"+?K=: M2L_:V*1FL#^OH?O2:.V84_;H7 M?8\JV]M!\Y-8X="-8NWI%"%I0KT9,0[F^/\_+//ZLE0IRW2BM[PY5YG5$.\D MF@M\^Y6A!$GPN.D@14N\X\T\"REP*%T*LP67'KLW#NT.[YN>3_;+<=KB0Z$_ M)8/_&\PI%%7=\#-9,UGR0-V/,,[6JDIDDI,]WR%Q>\Y.H]^2.AA5R#GY,\8U MYP\$>LL#V0^"<4V6^)C5S-M^G:V^ ^5(4J$7 [E4I;>D3JB+4'[$8"!WX>ED M;VQ,Q",+/J> 7 NVPEJ=(E9_K*WG%%^=HY06VL8-V3U$;>BYFTTO*LK4E<>2 ME\B[@PHY7%W=G_D8IGG]Z-8Q,6TK?A4YKJSRD6/K$>IBLE6(,C(GL120I7EP M458TXU;@YF@>5$YJX'T4ZN<4VY7L4TK'09@0K2CI4+&W?+R\)\#:@A@*RU&Z MU2AMLW93-QTED\$_;WKR,RYQK+[ Y=@+TO/(\6,.+VI:\ REV%2@$6+APS>R M$66J0.:AO:54IB+X)"1C!M@S6C5DK_3:FAQE>Z=AW=C8)TJJK=EX9)J"9$*Q M-C^K_C'RYVA+M57 YWKARK WC1:Z#7A*R.I@5'I[5WR>7%:KN*E+Y?OBPZY' M#VOI:4]ZFAJ;,K[W53 8#PRRT*V"+0I\]B(!:3PE>UN\3T1X+2ITR@]+\@)U MGQE*^RS/'.1*.'V'6=(??J==E6'^+B1O'Q"N^OD%[/6QT$'6MAF*J_7G)^K9 M>!.-P/78YXD7!8J%-6EQ7N'FL^F!0Y?,/535N[:%FH(%/6"N0['EUOUBFSB0DHZ1L[ECL9],>^B;!=]\A%62H:0QA':,@01!V?_\Z_/#DTBRZ3F] M8NVBQ<0RIZY6'Q79KG-IU6'=ZNFG0:-;XBTUH=]=P^M-ZX/]!!X%3XVY"DI- M 8\*%;";TC:*\NY!>4XYAW1"-LO&F! IR&AJB!Y*KM6!_XP3=>!TC0;>.=9I MWI$^%>KXTB@G_RXNNFY1D3"W>!L'U.H3E\B4(I].HJ%=_.@:@]:T30M?Z>A, M/ 8Y'C"U5V5.:A^KAFA^58(>$ZD-CQ'9&Q+D77QHHL9O"]A%*;9FSR5XG9MX M^RD:X(X4WS%V1JI/!XA5_**L9,>OD5KLNZV@9Y+;_];M:]O,9MM'![7GW0RN MC&B K?4Q,>T O"]9.(.4R 4_K7LD]KIJ$PV$K9G0E F Q+<430)EK1:VMIH"P/JG N#+JBV'<_PY48-%@%_.]\^3>$]Q,!1L M'!W"&!H\+1=@*_D?1"0TWWAILG$!G%[>OPXU:F&3IPE@:(7#35\DAP.RD9,3 M"L MC&<+!YX2_[D+BX2R]54V;L=I-B!!".7 (IN,);,SU1G']BS(#0<4-W6P M#C1RW]Y-CM1^3/ *,RGP%O#1PB*Z;\?;JH=J/;8[J^'?9& (]XQ5BX1 M#MA>ZVQ(*_!Q9.-2UKX(!^25IG7.Q!C9VLA9\VG[V&[(:Q/E $=&E*,WMH3RS#T)G8.5"G9$2(#DVDRJ?;4<=N,HE%YGO??4Q?7[DH .">#IOWN#1!E1:E^3X8 M(1XW9/$4K=BF2P]*D9WL0AFDYQ26QJ>>.8UWN7+2KTS!O[DS$$]H).2%IBHW M--YLIA[LM+^]4:G8J7RNE'K$_"WANH]1*5\CTK).(A;@M \^#?KK3-3_7057 MY-L^[%AHAX[L+/X<#;QL@N:Y%W1ZPFR\F959:GFT.&G$:<372TA'-_4B$E]' MKXU[OLYY_HE^S4Y9;%I&SRQ^X&Q^LE@7&.B&VRAK["JE=1 M\Q*?=Z5.R!+JF1V$LIYN(PH:IA@;IWD=S3;O_G#X3AE)WXTO99 Y8>9SSY?= M9N_9[H22]P:O@5H=B?27J&>&VW;D%V\OSLIWRGC66GT'5J/XK-0K-HHM?"IA MV= 51@?WV.^0'M/2<=)*1WI/$>)C@8E^D MG6S!?EP!-#42]&BQG * :=GS3:VA(NS%DMHF9,2)N",#WAK4FN%62H_8]Y.S M#VO,BEO@>SFH:\#M1.U6K*/JV1 CY2C0'G-,5[Q8/(M>E%Q))' +*'Q14VX\ MDS3_E2$H[SXO1N&Y*9QR_V-W_K]4<-#S_P-02P,$% @ Q8%=421%W]]Y M"@ TUX !4 !B96%T+3(P,C Q,#(Y7VQA8BYX;6S-7%UOVSH2?>^OT.:^ M[ )E+5*42!5M+[JY[:+8W+9H4_1B%PN#GXY06PIDI4G^_9*RG5B6%(N2K?HE M4>SQS)ECG>&,0NG5[W>+N?=3Y_;J;P#\]<\O%]X?F;A9J+3PSG/%"B6]VZ2X\KY+M?SAZ3Q;>-^S_$?RDP'P MIOS0>79]GR>SJ\)#/O)WW\U?QES'B$8,4!AC@'% 0(RX!D3+V-=(J#@*G\]> M2JHP#8,0A+X, 4;4F#$M <(<(^9+CGE8.ITGZ8^7]@=G2^69Y-)E^>?KLZNB MN'XYF=S>WKZXX_G\19;/)LCW@\G&^FQM?E>SOPU*:QC'\:1\]\%TF309&K=P M\M>?%U_%E5HPD*3+@J7"!E@F+Y?EBQ>98$7)^5Y<7JN%_0MLS(!]"4 $ OCB M;BG/WCSSO!4=>3977Y3V[.]O7SZTAHPGUF*2JIG]9C^K/,GDUX+EQ07C:F[0 ME]Z*^VOU^FR9+*[G:O/:5:YTL]MYGE>\6I2Q10DCB_*WMF"3 ? /A+>H8ST MN#+=CX?"^!2G'P\&]]+4!W5\P%MA!D->G5#O4CG6N?L0:C#TXR,^U&F1%6P^ MPFGQ&&8+\MR^<&&.UF&LHR>*:1EG7;JWH*J[0J52K:IEQ;67R-=GYF@J53+] MGB>%,3S/%HN;-%E5[N5481U#!#E 7%" N1* (R) )(1DE!/"<#PM'D[JJ4K! MMZ^;^&60/1'.''(K6C2:JV5VDXO'U6TQ;UJRS&IEUSPR\:42 M+V;9SXGYK"$ QO8 V /@PW5K\%N[WTGM"WR;;]"R7.SA>FTQ$9GI=JX+4*'= M=H<=TRJRCM_]BD 3]LS+REE7_^26N53R6G M#/LA!)S"".#0-*14:"-JJ0().=8Z\KOJN3W,J8G:( 5B"ZJWPNJ58+MK^PE> M]PO\,&P=6>7]B'(2^WX>!BC^">>CR7Y_@MO:[V#M7@#>I452W'\P0VY^G>5E M/3%S1V$BW:1%?G^>237E2L4RPCX@46C'3:@!BZ,(0&['G_++[#:=*F5&!@H#H*",38M!"& <^6;BB9@4 M0L>8.A:66HP3+29KG,\]B]2>_!:K:_6H$]JU8@RB:9PJX<90C[+0RL'@4E#W M/++\6U.K2[[=U%WF7Y6X,?/)/42SRZ28JRF1<4QB(VB$) 18A!0P034@]A(U MDD1IB;KJ>]?YJ0F[!.5EVH/H[[-_>!NXW35=8V^_F(=PI"AYM(6[,>(M.ZT_&$ MVII01:KM5@,;Y_6OBR15>"2"E[M<[; M44Y-NKNMX?K LV"]3ZGS^-U$K&,+W9>ND9OHSDSU;Z2;F#A4*UWQ_6N:Z:;T M6MOI1N/^#?6[.W%EOEWUT7SC4Q0J@4(= R&I::IYI '5L00:4Q;'$8.84]>F M>CO J8E^@]';@/0L2O>^ND)B]]ZZ+S7'7K;=6.G57C>E?H 6N^)V]#:[*:FF M5KO1SEW"=K!^FRM67M#U QT1Q6(@$1=FT:9FO4:1 ) 1%,8QYIBPKM+==GQJ MDBTOV5APCA?%*V3MEVA?"HXLS8[9.TFR*=4!4JRX&TV"34EL2Z_Q_1Z2RWZJ M_"U?%CD3Q91*23%D)OV0:X!1'(&8(0T4"P*EL2\#33IK;MOSR8G.@O/^NX'W M/P?950CKH+N^-!Q;>%T9<)->4[9#M%?Q-Y[XFM*HJ*_1H._,>LGN/DAE#O5Z ME\K'FP57^51HH@4UB(S:+TJ M7&^%UW5V;2.XZ_QZ -K&F6'=&>LQP^YA8_ 7;?!_J6A_?) M7*U/6,PU59P%@$5^!+!0(: 1,O-L((F(>8 %%6X5X='YB18!"["G[+>(ZZKT M?G2,(^XN3/20I\@7G;\:E)\N$6+@NNNQHK7.U78E\&CJS";LD["; I MTP'BJ[@;37A-26R+KO']OFOAN7&4L_F'5*J[?ZO[:4 D]$U[#&!$0KL@$L 5 MQ$ S*8D42A 4NBV(.Q%.38+KM6"-TBMA>@:GZ]JX2V37!7( />.LDMV9Z;%6 MMF0_>,'<]3ORJMF25GWI;#/L*^=W"Y7/DG3VKSR[+:[.L\4U2^^G)&0*2LA! M* ,CZEA00&.D0,PUE#3"0G#M)NK&.""MZ8[D+9#>#]GLRF!'$*J.8B(7=$U MM]>@"3&U0"EJU"^8AEW%7_%\:G)_ .=9=-WE7:5KOZ![DW!D"7?,WTFRC;D. M$&G5WVBR;$QC6XC-!N[2L\^2F'^^RM+-=9)88XBE%L G@0 8"T)NOD+#/)ZD3O7^VG!( H]<(09Q-^2)):VD'.ZY)?40O^KI):W)/O$, MD_;/N)>/RYS9YW1^O5_P;#Z-,0NTY"'0H48 ^YH!1@D$OL^%'T S4P2==Y54 M/)]:85B#\U;HNI> *EW[]=Z;A".+NV/^3C)NS'6 9JO^1A-H8QK;:FPVZ+]Q MY.'9CW^8P6"J^DM 7@M+.=_\W1C@U*3[LIEBA M] Q,S^)TWU52)7*_. ?3#IT5YQQS#2&J!(:!Q( $.HQ!P'D6 2^E31?T H\AM#J\&.#4QK\?* M1Y".MQTVDMAUY.Y/S3C#=E=6>LS8S:D/GJYWW(X\5SO-L\TJR>@KZFV?_!U!+ P04 " #%@5U15P0$@K8& " ,0 %0 &)E M870M,C R,#$P,CE?<')E+GAM;,V:VTXC21*&[WD*+W.[@?-\0 TCENE>H66F M43>C'LV-E8=(4VK;A[GF^5B M\@V;=56O#G;Y'MN=X"K5N5K-#W9_/_\ ;O?GPYV==_\ ^.-?GTXGO]3I:HFK M=G+<8&@Q3ZZK]F+R)>/ZZZ0T]7+RI6Z^5M\"P.'F3\?UY6U3S2_:B6""_?AK ML^]C\<*9 (Y[!4I)"U[$ K9DSXI(Z(W^YWP_.U1.2PV:90U*.!H62@:AHA*! MY:BBWDRZJ%9?][N7&-8XH<6MUINO![L7;7NY/YU>7U_OW<1FL5#[]Y,OY:;D9S[_UT\^O_AJZKYP;2M'SZQZ^GG],%+@-4JW4;5JDSL*[V MUYN+IW4*[4;SO_5K\N*([AL\#(/N$G !DN_=K//NXXDP^;^9H;R_Q8'==+2\7^'#MHL%RL!N) M ^B"RYGPG>6?'D\P_;6Q90R>&L,*!85!"$*H,O>1FD2 MHGVL0>?[FIS?A&>-:6]>?YO2Q!0F[KL/T'T QN^#\],3HW;!>FC2$P0>@WX_8GH9&IH(TD6UR __[G:=(2+9UD,J>A>H$:3+ 51!\CLF!;FXHK@)-@@^ "7?V^R%@QXO#J_6 M;R1Q/\.FJO/[5?Z%&)YQ+666K(#A)H*B+ E<1@.,1'$BA8QZ2 >&>]%@AD_ M":]7=!3GR"><5YT2J_:WL,19%$4'QC6@%90K196HP*=C$9WB"9TTJ@Q10CUG MNQ<0=KQ ;*WG*'CX4"WPMZMEQ&863,Z:FP)<1T_'6J"<2,D F65ON'0ZNN&2 MB+_L]N+ C9V#5^HX"@;.P\U))JVJ4MTUN^X70DF-U)FJYV*08+:>:BC%&=@2 M:7F!LF26!@/B!2=ZT>''3L<0"H\"E?LBZI@^?FS.Z^O5S%FO"D=*BHIW7:$= MP07+@/PO/K+,!!NB8?&"^7X-+#9V/K:3=4QD;(JEC\U94W^K5@EGNE"QE&*$ ME%VA!(G.PH 9(3MGLF,^9".'QN,''_HQ,OHNYP "CPF4LWK=AL6?U>6FI*8S MT3K4#J)VB4HK6R#D(,%KK9-W+-,F.30FCSSH!\F(.Z #B?O&B'0[X%&#X:[/ MPJ1&]);R:$V)E+;D,HL6>!8:32P8PA#YQ_4&V=BVX<(#)FPQGKA$QL MB*>6^]$PXB;FEF*^,0KG3>B>=_I\NXSU8L:]9-'0X>8P9W(\>? F&, BM76< MNQB'2!D?&>T'P(B;EJ^7\*VW@?L;_.]OTD58S7'3;37)96D$0DE(28X4&J(5 M%B0+7$<3HQ[DAM9SMON1,.*VY=:"OC$09PUVAQI2#;RY0=<]6M9\+.3'S%*= M@RH+2G$,G6XR4DEL#(+44AIE,Y<"!\#B90_ZP3'BKN5 XHX+D9/U^@J;[]>" M4COIJ"J2R5!J7"*"]YH!1B&# M\M]-?=U>T.(NP^IV9JRV)DD+2:@$"F4!3S4T&).,R:21E.]8_+,)\IK06WN@$5G#3Y= 60F(!N.;9I9+D,$WN1T;[D3#B MAN7K)1PL]N^F3\0[I0N'._<_="_=(_N'._\%4$L#!!0 ( ,6!75$#N/H' M%S@ $3< P 5 8F5A=#$P,CDR,#AK97@Y.3$N:'1M[7UK<]O&DNCW^RMF M%2?K;$$T7@0!.2=5BNTDOAO'CJVSJ?-I:P@,2<0@@. AB>?7;_<,P#Z>GIX?_N/MQS7KU[]:;UY M]>KMS5OVZ\V'WYC=T@UVD_$X#XLPB7GTZM6[WR_8Q: HTJM7K^[N[EIW5BO) M^J]N/K_"H>Q749+DHA44P<6//^ W\*_@P8__[X?_N+QD;Q._'(JX8'XF>"$" M5N9AW&=_!B+_RBXOJZ?>).DH"_N#@IFZJ;,_D^QK>,O5[T581.+'>IP?7JF_ M?W@E)_FAFP2C'W\(PEL6!O^X"'V]TW8<;AN>W;&#P/;LGNOT7-WIFAW;\]W_ M-0#(5_"X>B_:MMI\?HN#(K!E:'KWU[,/%>(^^*21V$_ MOI+0PJ^]!-96_>PG49)=?:/+_[W&7RY[?!A&HZO_O,Y"'OVGE@->+W.1A3WU M+__[P"M_=#23F6I"\NQ^$ MW;!@GMQWZ+?19IDA4YNQF$6<#^*'D&0"D9^3F,>>S#I/!07D9%OO=5V?6J MY#A780%S^ ^OTVC#.C\E.2SIL_"3R9JB$7QQ*^)2L.MA&.0%^\S3,)!/W8IL MM+"XA\CY/+*PG&@?> 3PQ1K[=,V^^\8U#>,U^^@725=D2CQ-3Y,$V[^8CN%9 MPE@O?[_^\O;ZC^^^:;NO?WIW??.]QHJ!8!'H5%3/F1@FA6!#$80^<%@A_$$, ML/9'S$^&*8]'K ?Z. =UGL3RQ4!$(=*))3T&BCDJ!BR,>TDVY&A%6)&P<)AF M0$KV=PEL4L@'H[ G&(\#F"XH?0%C ]WA>Y]G N!) CZ"GU "!#XCN1PFSN2, M?U?"(.( ?OTBTD(,QTBW=(7T5F/YII;E7^&["+_/V4:PUE"F/$"*74:B5UQ9 MJ&BDN(> E;BXNC3<=%=6:CVF0YXSG;T;I=#"LEEPW:H]^#(,$-;N GBD2 M4%3 3DK; +N], R[U6$ 282\2JC>#M7<'P">K9;^+1L)GEVBWK[$3U.XK['> MSY*[8J"!VLC3$!0-"C0H".Y+^7_S\7_>O[TT/*+$=I2H-.8$[;]<7W]BL2A M)X/^5DSO3%A>8Z!3VRWO6_QA1CR( EO*0C2G='CP5YDC4=[]]/[F[;6D@*6W MG!D2F$ 3HL%N:'#M_UV&X%> !RE=F4_@B& 8^B&)PR+)T,EY*0'67W_^]$%^ M,EY_SWB>"W0RLF3(.,O+;AX&(5=^S1MTGF,!P6H&$B8=F\:Z%Y_ 70J1#Z1_ M]>;=1X!ZB/$SW]"77A)$(">'O=%>>>O_)[E(!^S7%GO#TU1DX&_/KG 0BAY[ M=R_\L@!'E'WL]4(?W"L@VZ+WJZ$7B\@0@72 -_.\]BY2^NL_P4W.!$O!/4>? M&[QI'L=)&?MH.7G![N!W'S!P"S_F201Q4R$#QMI'KGWGNQ#\\DP%7JL=(,3G M"C4U8["!(R#R 47E#W@4B;@O0'"XCZ*%/P]Y]A5,#H 7\:PO6@RCV)S!_W$( M*/*"R[00K$7%#QAI%/7T2)^PD ^@.L3)X@+$>8:8, H?PK#74<1RT<>G\_KQ M+J:91)[#2'&1A=VR4'@K$ 1Q[PL$N&!_6("'+F RT%@*T0?";K11"^?B[Q+G MA.4I9P4F>L,S4 8^&TYTR&T2E4.!0X9RAJG A'!V92 C,>N.5-#'@9,&->9J+9?"*F*1Y8,P;4(4]:!\ MO)WBRACHD25E/LV50%I 9K5<"%\#,0Q]#<4& ET.HP;3\:Q06@0(@V3*"U#U MHC\"5/\I)#N%@'@EA&5?L2@\=IV!3@QE/N8](!"DI2]0/GV>\FX($6\H@/9W M@Q PC;(LX@&F;V"2'")L]5M$+"]Z-)-9BX:. 5)"J+()" M2:7;1-:#1X!+ 0:9>E8X!OS)Q-*_195JR.%#BAYN&4ND*LCRTA_(L<1]"L/@ MFTE9X*!)-IQ61Y@^P* DEX.#,ZPIK5@DZ27R5R7MN$P,8$ ;?(NH,773:%5> MPA;2\+!MK5A:NG#UZJ\R@1)]*U8FH[M)423#*WWR"N^"\@=-M_#*2B#FL[;K MY=#M<<9UD$V\">5SRZXZ/\8J,\^]-SPZ8WS@T;'6.?5@UD>)K2 M1\KL*:^C9<_$1IA7:*X=^D7J9J7Q'L67X[7TF;4Y>LM3YED<(MJBP^ -E;$D _B21Y%,L,.4PT=3!NLD6M8,,_@.%Q=VBUZ75)($( H1W#5>(B?:@Q1>;DQG!; M[OR8;?/)@I/$EU(9+)L6UP(R 8Q1H%NN_#IX'R(!" /P];E$Z'C\@H=1#BJT MCY$8.K%+1DXWA6K;"V-I,.E16&USH;>;SST5XL R*CS[/RA6@6Q(+5O![3;B)-_VA(EP#6*^*$.<%7ZHXS%*KDJKI MK?%M=,**:'*]X*US<:!@Z$T2 Q?*I,@;'D6-=3265$O(%,H DQK@@H"4H5:0 MIJ9>$.C""/,3-X,RRP,.[RVM =$P&]J6.6==9Y\^L'>8/,G@O7!LC.10U0NHTM+<@#XHU5A/VD&R8M M4%?[]XV689IG_B"\50G *4PJR2VP, ;(4-PE\(/XFF\FM>N6)NJ'$LWK;E(6 M,[GU8Y+.,&]8[9(RWLK9$#4\_L+F 82=8,^S:J\8Y 2SJET4EP2 ?S5,+T,TE?N?L=W''/B> TB=JHV?1)=;!S#POI9<#+/P%'53)=Y_'D=7/ M278''R]_2Y*O^/?XF09G0]&3"^HZ]BJX _,/01 /9593KBBJ5I2/5R0CT"I2 MK&*)>OND[#?X3U]) MW6F4X7GM21P+_@;H!)@4AL$8&]T639JW:I<#)LMQOR17Y9_C/Z72 MD1%.EH!ZPXQ3M6N)3@]NN_NBSC7U2E GE?<"2FAJ^4.. 1B3N_1A+U2YIKLD M"]1^#49,%1[4KHU6XZ#Z=I+%FO\%O*!PN.1[W-**@_EOTXC'\]]5@>'"HUDR M#"%LJ[^6RY;84W#CW^"Q#25Q\A!X#&*NBK: @G?W?)A&,H9\B"\J'IIA%:$" MO4D. @D":,* $2/0:E=R$GQ.L MI)#"K'9I)YB$I4&$#GR($3>8UBJ<]Y,R"M!O0$\_0.>AP Q7E6="%T/A G#> M\$T_VL![4/5/,Y%65:8@Z7T.#B1#1PJ\(_"=,4&85^Z@*K4!00E"3"0QU%,( M2312(K.,0QI6.'0%,X.PIUD"'+ @#F!YA5_5PR)5# M%!->@.?IRUHII<^4B,B* %5)$8Y5#$H0_*321W6&"L#P%L! 7QA?3P>C'(LA M*M&;WJA(NM)J8CK-S\)4C?Z@2E(S*>'*E4++RXS+N!LU$>_7GG@X[$+\K5P. M56Z#%N>#C 1JGQ8KOS*9-TKY"%&]QMQSJZQP5TTJEP/^J*PGJ]7T+:KS&" ; MUA5J.4>[ C-L1@B4@/+[/08HO#?XW17#+XEABNB".5@-7#J-0Y6(2TD!BIC M@,^OT.>UJ97Z'!S>:!*+%.-2*C"R_F "TZ06>ZE&7_5@E?20N?O9&&H2A %G M2V9=BMF*.60-":IC_",3524G6 RLB'N?JB(D 3\O$Z@0D7SZ_]K)X .N2LI)!).=/ M6_90%A )I5W@9V":8J0&QI^RK*S$!M8NC5!>[T<@09&?RKBJI@-/:Y2#G93K M^.X;N_-Z+GLT19GZR;JD$%3D,I$+HJFV3YTP*+8];*@?P$P=;_EX!_![0H1)XQC5HZ,_@ M+["?%=ASI4#[LT@UCUS'<2DK2=060HR!U9 9^N5_C_?3Y'Z .A[U5OCR=!2S M#*TNN%#%@/A??+C1Y)BB!VL>*::/,,Y3XX\5Y]4^R'2*HL;&9P-WFWYH[I;_ MGZ"#,&%38& 4HQJ-ZJ@7RQA+^-,'K)7GWA?S &O=T:F8^[Y1,RO$.P@S[UIL5]$\>^&0CDY-?$_X#=-#E9H MU:F*R4XK6O#K (+ 4%9%3QVT:.C27KJZ_CWS=/>R8^C6TX&T7*>]Z^-+#^2H MZ_T^E1:0WJ5COU[(6I]TL;'A'7.U\7/W8%A/CV^@, \+*!@<>7Y)%BY.M@;0 M4'\ OE\)X9!G?>!*+*62[3.60:R.3(SE+@-M< F01SS- MQ57]X740YGB.XRJ,)23RI?FZ+#FZDMR*2SVOU3%-Y/\"I+,(ZFDJ'FY)T7A5 M!(N_V>V6KJ_^66\9*W][:%B0*[=M;C7LP[_9GD/ 'A>PZPW[2G*NXEZ0ACSE M\3\NK+%FKDSYE@N/FND]/KPHC MUCE*4GJGITX)2T=7>8R8$ M'EHN!CE[AZ'C6+?,+^QD"WI\K6^E#G=I(1!@WR<>L#Z>;4="TX2_WX-%JA<".ESP #J?'B]BF,@ M^G2&[*GK7"D')X6OJ=8Y3U -)X428J$GL= CZK7+_:_]# O_+BO >O)_#RWV M0;V[*CF#36UFV]QX.TLI/=J&4Z+F\[*N/'->ZTITK,T8.CN I5H3 R_F)6EW MJYY>K>RPVH#E&H:M.>WV;+/5G2\=?]T0!0\IH,?D<5Z)$>.>(N,:FND9Q+C$ MN,?%N);1T73/(L8EQCTRQC6!<3M-9=R-?7C?%^(D??B/RGD&>Y/S(:IF.UO%(6D^.K!1C'\(7>%,U M.'F*-U M]C08T6YKCN-NYW8V1KWL,& X$:H:FM?>,M(CJC:5JH;9UCH;&PTB M:^/):FH=PVDH64\W+S#=[IS2 HZK>6ZGH0XIQ1G;4M73+,LCJIX654W=T'1S M4_^.R-IXLMJ:U6ZJ#C[JI,#*4PO+*3%S$\JW3\D2-(GY-D0"7NARD/VH0RYZ M-;'/<,=R4X8Q6UL&I\0PY\DP1FO3G0UBF+-F&//L&:9RPVI@ZB=MR0Z[=KUI MC-,:XZA]^ >3>1_'?:3K.XMF^GT]BZZE,9HS!AWM',>N(A99U>:,S[0Y>T*- M^!)L'=IU>*2^0NMLFTDYTAS8T=#&]#2GO66A&M'F>6GCM;6.17+32-JX'K10"T,SI_91B@O^D823-I8VKM#M&FD;2QVIIC M;+H73[39#VW MNJ;^CU'?/JJN;;U32:"L& 1;L!6J9PSBEL=S78.Z.*1^[V: M-&W-;6]:*$^DV8_7XU)&H;&T<33+I:BU 9;U-J6/+ ]T0:Q]E4A1-I]I,4UBQ]R^,I1)IGMJZZUC8/2!N*6V>[DQNUX:&-KWK8A!-'FF7.DAF9;M(/22-K8EN9Z!ZR8;9IG1V,1)J%"(3>7&&A= O/=U<=L8.3!13LRR7 MR-(TLMA:QS"(+$TC2T>SVH>1%BIZKHGP&YXC2F(F_B[#8L2&HA@D 0OC6S"K M6/S\E%*M8PMU#W['&.4A'M 63GM]54$T(8$Y=^*\--L;^#S-JWE6N'676-EY M@]D 9*MT3)S$EPOE6QJ+Q9/N3S@>CK,,BDD;1Q37WL!P$E'V%/JX%(\VCBB& MYAK66<2C^]NGJ&J:IW()U50!^QF&O;&'AI52#:6H)9FVAODLXB@32=H M6[.]#3Q:(FC3">IIMME @C:MQN5$:VX)2*I>?LQ?K:J7NZ*79(*%ZJ^"WS_M M%-[1:$A#UYR.30G=1M+&T#H;=_$BVNR%-F9;\VR2FT;2QK(UN[/E,=,&[866R'JO :1Q9/VKF:Z M6]Y'36Q+;'NP-)BC&3JI6^+;(^-;$_2MLV5SD'/>@;1@24%2=B/1Y(TS@G+_ M4#;E%)>WOT-Y// _] MY=S_Y 3>T7E1RQ;61$=);YF;[M8U+U=,[-5@]MHT>B3V(O9:G[WLX[\?GMBK MN>RU<<[VB'?LFNM9O@VCLA#!AK[E8CKG@5CW=(1K\V4W4_2,IZ?O'EGX\>2= MB7&/B''-I^_S$>,>GI#GQ[C;UE03XQ+C'I1Q.XUU%6BKCZ \.BB;$G@>?*OO M3_F'"!@'T'E?L+@<=D7&DM[,ME_.DK+("QXCZ+0'>'YCT![@&GN 8\2<4D&_ M96N6N>DQT>:EH$^3-I;FZ73E=#-I8VNF<_Q;-Z=)&TMSW4WOGJ1]CWWO>ZS% M>T=W?-S1G(TK!NAH_[YHLW5--=%F#W)#%RXVE3:VO>5=SCNSIZ\*WHU$;4/D M/PJ2+OXX;5^FS&&U#,N!=:9)'N+ELE>9B'@1WHK7=V%0#*HU3K^E9K_2)Z_P M;IZ@)5MX9240T__BT&'PCXO0USMMQ^&VX=D=.PALS^ZY3L_5G:[9L3W?_5_3 MO*A?&F03F]X7E]U,\*^7O%>([(I'=WR4S\(\#..::&T;5KL(:#CL,QX5L#S! MBRCI)]PPC-9?:1\X-?.7?CV#1--+[^MA.TYZ?[&XR.J%*>KZ B_=VA&WFH_E MO$P9P8?)C8C$4!392&/O8[^UDCT."^B;!+VR7 0,/LE#.AQ3=3_QB,>^8%\& M0LQ?J#)-<)[U@>;RD$^5C4YN*J_O Z"/,TXJ.K,)80R9?F MQ4_B14G!A)%:NF*FRK&MYJE^;LF?YI2"^JVCMSS76OFSWC)6_O;0L(;9ZKCN M5L,^_!M(Y7, :UKMM89=L>'2?F##99VT8);Y74A[GF17=:\J8ET$( M5G8=AGG6;9@]=%%]XA[-_ECU39EEP#.,YSEX/-M?3[S#3>=G&X-R@V.J\WS M0'DS'S_@C8*W/%I]A^"3H^EC+6YJ?/F2IVOF":1NB,&:RF".JSG;MLPZR'[. MR59'_"IX5 Q\G@G&?1^67.0L@W@$5'WR.?3%L6VD&(YFNIL6C33/4SI-VK0UQSST)A#YC)YI.X*]69I #$2'J=N%N9#L'\;'\[_;&% M08ZE&12B-I,V;0=,_P&[H)Y"%=6J7%3!XWZ(A;7*T=Q>X(\M?C%,3].W;05% MP>7S$Z?M'3#R/UU#_TN2!'=A%)V%5;?T-O 1;6$WE#C&89LSG*Y=?RMZ(LM$ M@/"5$J=@TQ_:%UHNYCL[Z]2,RN_E"#C9*Q*7+[=C=33=:S=^HX)N$R51 M.?!R';>M=28'I\]>5*BK\9Z@/%UOX[?WUS^]_^W]S?MW7]CU[V_9EYN/;_[[ MUX^_O7WW^0S MJ3*]KL^II'R$AU3.J)C4-$[B(.]ITL;6#.^ O0OI>,J4@LA*$4S;AC,ZJ&([ M6MLZ_@MW3Y(V9D>S-KYT[HA3B\W5$;7_F"89]H_$^S9Z82S;^D6"YX(E75@* MQ]_.Z;2*V::]QT82QO*HO48SU4:4 'B%R(8L$-WBC!P-F4,Q7Y.GT43B6)J[ M\5V+1^QH['L/TU],/SVE.NDTSB4YKJ8;)FUA',Z=.0T^:K>U3MLF/MKE\;9C M2'$?8YI\?]SYV]C/W"AF/>6@R#AD4$31Z@-IA(UK&X\X6CV$"I@)-4\YCC': M'0H6_J'LTE.%?;$:\(BS 9:M:QVC^>F 39%^1 [)B3"2X6JN3FV3FMHV M:?,+=XX"R%,W5GF1^%\'201HR>NR:NR^5(S(=EF>0RW_R';M@)$<1_.,#C$2 MV2ZR7<\2:,FN@>O;LC4EH+JH^H'#6*=S#G.KE3=1V1[+L>5M$'Y@RTUB<[IB M(>='O!MZY>WQU0HM!U"0)GF(N_I7F8AX$=Z* MR9WOW\Z6RU:KT2>O\"[8^;)8?&4E$-/_XM!A\(^+T-<[;*T1VQ:,[/LIG81Z&<4W/ MM@VK700T'/89CPI8GN!%E/03;AA&ZZ^T#XHH\Y=^/8-$TTOOZV$[3GI_L;C( MZH4IZJI+DG9C$F3B:G\*DQL1B:$HLI'&WL=^:R5['!;0S\)/8A\\)UX7 MHOQR??V)%0G[/8DOY>>?964*S,0^")Z7V?P9K,:LY8^29S!G-)K ?AW\5>:% M"-COHD R)$,AW<,''_@D,O9EP#.QYN*H_O ["/(WXZ"J,Y7+D2_-Z2(ZNU$'%^I[7:KL6"E7ET5?35(+1DO(V MISW5;[;=,LW.RI_UEK'E;[:WW:@/ 0LJP.VL_IF /2-@VVL-^TB4NT'H_7C" MREAX=HD/J]3!<[IT[GI!\B 3@GV YP8Y>Q<'(IAQLM;$VP&<]/GE+?<;7Y8Q M+X,0]/CW:[2-.#':?A%I(89=,%J6KC%3GSCNQT);.8 J7J-E'T.SGV MOG6'M(+G-]7!W*IT9UUNM86BNZ^XPJ;F>;]K0LV@D)B0F MR\5$UYS.+HLT24Q(3$Y/3)P=ES*3E)"4G)Z4Z"V#/*[C+<%:#]_CS30N-]/P MKM83;^%+8QQ_OX=5K%1QT/] <_Z(F\"+O(@R1!FB#%%F1Y316_H9M5MIB 6^]O\N0U5CR?@0.S+]6Q7#O>P^Q1CO M\.33L;"OK>GN 5M5$F6(,D09HLS.C+%Q1O>!-\08JW!8W*^!D\O*)-N=-FY>F9AOV^G:9J+(7JN@MO7,0HIQI3/Q^F')EA7__^!LKBS : M9Z@%Q<3'Y5,2;8@V1T@;6_,VSE(39?:4I3ZC^R2? :TK3MW--PAYCEK&Q]Y[ MM+'1>15$[QXK#:R8-CS-:#>^9GKGI#APG$:22)*X((D=S;-($DD221(/+8F. MUK9)$DD221(/?I[/WF4WY=.6P^4M8VO 5_7*?+B9+'6>G/^-^B,2L-1YLK'M MJZCSY.G2=K[SI.$=&VWE,-1Y\AEYA#I/4N?)PR.1.D]2Y\E=HX5[3\R;4+(S$Y- -6COM75ZQ2F)"8G)Z8N)JIKO+N\])2DA*3D]*])9) M0G(Z59K4>9+&H,Z3.Q4>ZCSY)/296MMSZ4@$488H0Y0Y>LK@F=[S.4;4$ M, MG2=WU]+6<395+#L\F$Z4(H\>:S.)'5R:"YM.NX!_7RB M"]'ER.@"@;%)@3&UH#QREY+:'!)MB#9;G.\Q--O:H#4T464O5 &K?)B^H&<: M'%,+2@J.B39$F\.VH-0MHDP#*4,M*)^E@I5:4.X+T]3D9[9*Q]!,A]K\[#E. M(TDD25PX$>=JKFZ3))(DDB0V0!(;?Z"())$D\=0E46^U39+#38+CA1:4ZS2: MG,DV&VXM&&$@,=X'%1 1S!47^7S\LL;OP#3A7$A^MGD=_52 M+"?WRRR#:>MUMQA;@2+#6X8BL^4\@B)X9&/H[9D7-@%_?7FX.$(IZC9=BB1] M%*_<"0;D2?HQS 5$M:>X0%+9:G6F>;0JW-3@I3P5?A'>BFB$?RGI $;"&6=. M6:P0)& 7D+P099#GN2B0I_\4;,!O!7;\B\H QQN$^7:CJ59X\>S)97@PGG3; MJC@? <;GQFWS>,1B7I29U 'X:[5H /!F 9X[GDL$9@@N?.:@%H9I$J/LP.N@ M**.*2!\,P#O,"9[F=C'K:LN ?7!8Z[B,6Y0ZY#LB#AB$38-]1$K -(!AZ M9$5E(?H\E-P'>F\L(J!J>SW@-E"6P!$\ G7:'MU$)=B7/4\)2V#PM,X %WI\Q/ ^;@O76%B5Y7JVM,R/^ M"Z#/(6#'2SEM40@.+@K*+'P6*=!4%OA)MIDI_ZNUX7R_!\8+^=L;T&X\'LDM MW,YK^#J.2]!O:@!4:S@RCL_? 6W:N*C&C4L'-I33,08/#V M4$Q74HLE2H=,45R37TP7H0![H/FL#"7,)_4&2'8V I5RQ[,@5]H&- ':9QC_ M1;NESSH4]I33&U;U+FOX*=/^1HOMB+>V_:V>K2*/Y0#]U)(3B!=1)0*<52]_ M%=E.OU4%JOKD%=Z%F+0L%E]9"<3TOX-LLOJ^N.R"GO]ZR9$OKGATQT?Y[/3@ MA-1\U0866C)G..PST-D J>!%E/03;@"__97V+UB>^4N_GL&'Z:7W]; =)[V_ MF(5WC=L9GBA/AOE8CD/*\$]AO?PYC#H^ <'\0/ ?G-6_H6OXE.*9B+M^BUEG8?&?8#;>J2T?A?_"! M3Z FOLRTR:5[/.BV"0*6[O$XVKL>?H=OZ!J/DR3M_#4>IGYLM)7#T#4>S\@C M=(T'7>-Q>"32-1X[OL;CO^@>#[K'@WI*K[E:2QX&;7KQ";5>)S$Y[/F!MN;9 MC:]:)C$A,3GTK?9&\XO[24Q(3 Y]Y3P)R>F<=:6+/&B,YQKC3)NSS%WDT:.& M+!NAS] ULT.=)8@T1!HBS2F01F^9![QDY4Q;EJZ^RZ-/K4HWTRR&9GN;]MS= M88L_(@V1ADA#I-FA/;8,NLZC.==Y#"A IJZ8)T(;0S/:'E&&*$.4V>1*CP,F M+LXT/G[\2H^0XF2Z-H)H0[1Y[K,^'/)_9,H_L$K0& M'3Q[8HYT!_AV'FT.M9P"_\5N$GB6!8G(69P4#)90=V272X3U/$>[D$W&F*+W MDEM%=C$#07GT4"Z_^Z6>:56OU8?["E/;TOG?J+DF 4MM2YO;_(S:EIXJ:>?; MEAK>L=%VI6=*;4NI;6FC$$AM2ZEM*;4M;50RCMJ64@>M-?/]EN9ZC;\SEQK- MD9@AKZ-Y^J;]GNCL#%&&*$.4:1YE])9Y0,*<:4\6ZEFZPV[('9NZ M+Q)IB#1$FE,@#=CC3<]_[Y P9QT14\]2:OMQTK0QM(Y!G3&),D29C7J6MBD^ MIIZE1^Y64E],H@W19HN#/K9FV [U+&T85?2603U+J6?I,3J4%" 3;8@VF]/& MU;R-4]9$F3VEK,\H1'X&M%++TF=%Y'EUSW),K6TY3:^ WA33!PZB2$Q.34S: MMN9:%HD)B0F)R4-B8FFVV2$Q(3$A,7E@M4;+)B$Y4(IT!_BFEJ5'V&:3H'SN MEJ7K-":=V94PW%INPS@0<7%UB=_L*1=EHD3V6OM4PS#EZUD$6*VV@RO^.&WK(8@!GA1LN=R 1+ MLW#(,P"\UC(OK)8W?J0'DZ:\ ,0S'@?5@%%8A'VY5Z,QCL\;X^?+N,=ODTSV MC85YXSXV&I-@]WB8L5L>P218>3$YKG"9B8AC.R@?U@3+QKG@8QX&58\W#,I9M^68(5Q(?KJ87@U+W+Y+;SE3;^E@(_EC'Z993!7C9L68QNBU_"6H;,*[+9;[KK85:NPIBB&+TPO%A_(1%YDI5^4KU<%*P[0EH:KC()6^L+^\41JHC^@56$T;+L MK52$9"#%S'<"".XG_1A@0-DQ6NTQ)RAITJ=X ^A?U39KR("I0+83T4B;YCH$ M9>8LT@JN 8X&31&BSN Y\"**XY^"#?BMP,Z848DK* 9AOMUHJF5D/'N^'QZ, M)UWI*N&4N(/GQNTEP1&+.4B69'C\M5HT 'BS ,\=SR4*,P07/G.0@6&:Q"@- M\#I(!8P:263R8!C&(<@M1[2-1SUM*1D60>.: MP7M2/K&%)X0L*![*RD9)KDS0E('?SJK=B8WF,UOFC)Y80(<"RIPR*SM$STI# M-JVL^AP,&.B"Q _ES'=A,9#3 :0@AQ-M@LL<@@G^+>R)/WGA#\;KQJ7@4VG$ M3]V8A0<64[NERS#BLTB!CV1MKJ353.5NK:GG.[8P7LC?WH#FY?%(5E]T7J,_ M&)>@>]4 J')Q.&"A4]>Y?S6$F-<]D#76!]<4?-2*C&APL?MP33-0&N LHX"N MI!9+E"=TO6AJECK/<')FG:56FQ'K+<.6U84LC MI=:;Q%=2$P,LU8T< M*@$U_99*B%WIDU=X-T^P>>_"*RN!F/YWD$U6V!>773 O7R\YLL85C^[X*)^= M'G1SS5IML-Q+Y@R'$/%$!4 J>!$E_80;8.;_2OL7+,_\I5_/X,/TTOMZV(Z3 MWE_,PKO&'2M/%"G#?"P9+,7XIS"Y$9$8BB(#%_M][*]66X<%]#/XO[$/LC@6 M1:FA0=3'M2<_@\6%1T"^/PB>@V^=-W0M?Y3@6H@,/ L4X'\)C@FPR[>HAA8* M:=B[G][?O+V63U8?/\C[=;:2UL-?S>,ZQE97\W@MQ[&?Y4Z6]2Y/V018"&AM MVR)@GP78MFL>$[#N+J_F:< .ZE[NF/&.Z8J9FT$F'K@^Z!Q0L),+E'9Q[]11 M86WF;J*SXYG5JS\"9;AR[WV-2YGV=?O2,=S?@E'L4ZZ[V!J+F;RXAO MB&^VX9OSO =IZIZH2T:7(E%__C7/IV@=PVYZK23=8D%26U[#4 MD;KE;=88VS1LZOK50,I8FFEO:HF),ON@3%NS/>J4UT3*>)I-MZT=]KY3:AN_ MF9(W7(><^@92QM3:'@7"3:2,H6MFQR+2-) TVUQ#2Y'P4['^%L^&^N'DA/3, M0?PJ-J:P>",=8VAM@Z*O1I(&U+]WP'[81)K5WJRIN2Y%QHTDC:ZU]0,JM#,- MC;\4B?]5=KX!&[PK>WR&CJ6MZ29M?C61,I;F6)3!:")EP(?571*:)I+&TQSG MC.+D9\#KFE>Z5.TGZ.0,E7$^OEKPD1W#I#).$A,2DX?$Q-#:)E4[DYB0F#QX MPJRM.1V#Q(3$A,3D@=5ZAN8Y=,3L0&G27>);#K/^W2XR3IOJ<2![A*QG=:FE>;$:<1IVR#6)IU&G+87Q+JM+3>_SH/3CGFG8<.%K^R"/9QM?4V% M*ALBUG1:G8,4KC1&BHA=-F$7M[5I<3BQRQFSB],Z3,4BL):XMH#G6TU--O:LJ4L<2UQ[6%6VS8U9^/6970JX,DN?HKY M&-43)0B+,J,[--9.WQNZUG$Z"YFI#9F"6COLF"P=K>W91)6&4<7L:&Z'A*5Q M9+$TQW4.0I9C+DU>KPG*BMJ3_?O!"@?+ZMR/RU'>[7G=76"E@0=Z#4,SS"/K MHK(#4AQ'1$J2>$:2Z(++_J=DS')+$ M36+DG9WUV.?9C'_FLH/,)!8.8Q[[,"S[('@^DV=^X% )'N0->Z,'SZ(\SZH6 M^$BNZGW,D*JRCWB1L&(@&*RDC(J28"%L(SO@^< >L5["XL!JPO8I'Q M" ^J &NE>#89'REC64R39B%@)HU$#N\J3L6!_QEC:3C[4O "?GGYW3>N:4YX M>%^45 P;"%B0;)]^!6(B,GQ*=1!Z3GB6TT BPGC]O0;H#R7>\QRH$ %;"<:C M/,&&1E$9 -)\D"T.].B-F6]8,1^[&X3^@ WXK6!=(9"LU:%Q>7]+)EB<%$\B M91,)-I;&180P2!$@:<;E2 MPYE:#; _R[GK<9::"'DA\/@%*G30X1&'!:YX1['J2+Z*>@?K50-LG):7*0C] M$#NG3' H,8=XC!DX%TE6X(055>5S><&_BD$2@;CFP+=% Y#H')J5+6B'6<@#S::)60^6?,6C.S[*9Z@/_.7?CV##]-+[^MA.TYZ?S$+ M[YX9/A ]D:$'GI89L"]0OU8'DCDW]'!NPB&P_^_BCGU.0-*?!IK&]N]?23GG M]VALP-9/O 3EP* V14]HR@+ \R'H?GA6>E7X=UF Y?CWV,U 649M,E'440*Z M'60G&X&$WO$L0#NQB>8QO(ILHGG6USJ==;4.+G?G6@>X%'&) MYFV&837V#"1<@WP_C2J2X!/5DG!L7K *7 DCK*^,8^&#=>>9="[0"Y)^#4Q; MV_1N"595(-:4OP7(16SB3^ +Q1Q+SACPAHK'HG 8%FPD.#@%M\ +\M.,$R,= MXJZ(0G$KUG! $L R6VLZU:\"$.D)JVDKMH5O"C%4 M[F21@;SBV1@8M^:!&H$:^EY#GH%XLTCT 4CT0L#_ZPGIZ<,7/8&/(3?U%0<\ M.$@.&,@0.O@2'@+NP0&5# &FPG[%1#-B@F*#8I'-R *,ZT-8D$\S+A+QHU\D MW5I,PUBB0^4^A#^(07OUT2WU@1M@=LE9* R >>GKPMI\(8)E@Z.T9*4/Q%=1 MO;L8O\I4W M2 )X50XHQ-;IX >+Z;3@(K!*]*;LUT((6RK&5A9/S!BFR7#3^02IJ+GDS;GP M?>R'22T& U6PHG#/.EH3LS&K,-6RIBSGXHJDRATO!TQW*#4:Z"C07@^85Z48 MIUATP@OP#<,=&87XRRYHB& I^F%:GR/"U+3@6EQ*UAJ[%3##QUF<@&883;): M"ZD\3,X UZ++@-P(&(Y%MBCA6^Y3-"N6?-5-@A'\9U ,HQ__#U!+ 0(4 Q0 M ( ,6!75'FHIR1ZQ4 ,^3 1 " 0 !B96%T+3(P M,C Q,#(Y+FAT;5!+ 0(4 Q0 ( ,6!75'$0R0KC0( ),) 1 M " 1H6 !B96%T+3(P,C Q,#(Y+GAS9%!+ 0(4 Q0 ( ,6!75$: M\[9KA0$ . " 5 " =88 !B96%T+3(P,C Q,#(Y7V-A M;"YX;6Q02P$"% ,4 " #%@5U1A63[IPD" "-!@ %0 M@ &.&@ 8F5A="TR,#(P,3 R.5]D968N>&UL4$L! A0#% @ Q8%=4;$@ MXM\?+0 +C$ !0 ( !RAP &)E870M,C R,#$P,CE?9S$N M:G!G4$L! A0#% @ Q8%=421%W]]Y"@ TUX !4 ( ! M&TH &)E870M,C R,#$P,CE?;&%B+GAM;%!+ 0(4 Q0 ( ,6!75%7! 2" MM@8 ( Q 5 " <=4 !B96%T+3(P,C Q,#(Y7W!R92YX M;6Q02P$"% ,4 " #%@5U1 [CZ!Q